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Introduction {#hepr13438-sec-0001}
============

The Liver Cancer Study Group of Japan has worked to advance the study and treatment of liver cancer since 1969, carrying out 19 national surveys on primary liver cancer with institutional members and collaborating institutions across Japan based on its General Rules for the Clinical and Pathological Study of Primary Liver Cancer,[1](#hepr13438-bib-0001){ref-type="ref"}, [2](#hepr13438-bib-0002){ref-type="ref"}, [3](#hepr13438-bib-0003){ref-type="ref"}, [4](#hepr13438-bib-0004){ref-type="ref"}, [5](#hepr13438-bib-0005){ref-type="ref"}, [6](#hepr13438-bib-0006){ref-type="ref"}, [7](#hepr13438-bib-0007){ref-type="ref"}, [8](#hepr13438-bib-0008){ref-type="ref"}, [9](#hepr13438-bib-0009){ref-type="ref"}, [10](#hepr13438-bib-0010){ref-type="ref"}, [11](#hepr13438-bib-0011){ref-type="ref"} and publishing the official results of those surveys[12](#hepr13438-bib-0012){ref-type="ref"}, [13](#hepr13438-bib-0013){ref-type="ref"}, [14](#hepr13438-bib-0014){ref-type="ref"}, [15](#hepr13438-bib-0015){ref-type="ref"}, [16](#hepr13438-bib-0016){ref-type="ref"}, [17](#hepr13438-bib-0017){ref-type="ref"}, [18](#hepr13438-bib-0018){ref-type="ref"}, [19](#hepr13438-bib-0019){ref-type="ref"}, [20](#hepr13438-bib-0020){ref-type="ref"}, [21](#hepr13438-bib-0021){ref-type="ref"}, [22](#hepr13438-bib-0022){ref-type="ref"}, [23](#hepr13438-bib-0023){ref-type="ref"}, [24](#hepr13438-bib-0024){ref-type="ref"}, [25](#hepr13438-bib-0025){ref-type="ref"}, [26](#hepr13438-bib-0026){ref-type="ref"}, [27](#hepr13438-bib-0027){ref-type="ref"}, [28](#hepr13438-bib-0028){ref-type="ref"}, [29](#hepr13438-bib-0029){ref-type="ref"}, [30](#hepr13438-bib-0030){ref-type="ref"}, [31](#hepr13438-bib-0031){ref-type="ref"}, [32](#hepr13438-bib-0032){ref-type="ref"}, [33](#hepr13438-bib-0033){ref-type="ref"}, [34](#hepr13438-bib-0034){ref-type="ref"}, [35](#hepr13438-bib-0035){ref-type="ref"}, [36](#hepr13438-bib-0036){ref-type="ref"}, [37](#hepr13438-bib-0037){ref-type="ref"}, [38](#hepr13438-bib-0038){ref-type="ref"}, [39](#hepr13438-bib-0039){ref-type="ref"}, [40](#hepr13438-bib-0040){ref-type="ref"}, [41](#hepr13438-bib-0041){ref-type="ref"} and original article using this database.[42](#hepr13438-bib-0042){ref-type="ref"}, [43](#hepr13438-bib-0043){ref-type="ref"}, [44](#hepr13438-bib-0044){ref-type="ref"}, [45](#hepr13438-bib-0045){ref-type="ref"}, [46](#hepr13438-bib-0046){ref-type="ref"}, [47](#hepr13438-bib-0047){ref-type="ref"}, [48](#hepr13438-bib-0048){ref-type="ref"}, [49](#hepr13438-bib-0049){ref-type="ref"}, [50](#hepr13438-bib-0050){ref-type="ref"}, [51](#hepr13438-bib-0051){ref-type="ref"}, [52](#hepr13438-bib-0052){ref-type="ref"}, [53](#hepr13438-bib-0053){ref-type="ref"}, [54](#hepr13438-bib-0054){ref-type="ref"}, [55](#hepr13438-bib-0055){ref-type="ref"}, [56](#hepr13438-bib-0056){ref-type="ref"}, [57](#hepr13438-bib-0057){ref-type="ref"}, [58](#hepr13438-bib-0058){ref-type="ref"}, [59](#hepr13438-bib-0059){ref-type="ref"}, [60](#hepr13438-bib-0060){ref-type="ref"}, [61](#hepr13438-bib-0061){ref-type="ref"}, [62](#hepr13438-bib-0062){ref-type="ref"}, [63](#hepr13438-bib-0063){ref-type="ref"}, [64](#hepr13438-bib-0064){ref-type="ref"}, [65](#hepr13438-bib-0065){ref-type="ref"}, [66](#hepr13438-bib-0066){ref-type="ref"}, [67](#hepr13438-bib-0067){ref-type="ref"}, [68](#hepr13438-bib-0068){ref-type="ref"}, [69](#hepr13438-bib-0069){ref-type="ref"}, [70](#hepr13438-bib-0070){ref-type="ref"} The group also reports on the Response Evaluation Criteria in Cancer of the Liver.[71](#hepr13438-bib-0071){ref-type="ref"}, [72](#hepr13438-bib-0072){ref-type="ref"}, [73](#hepr13438-bib-0073){ref-type="ref"}, [74](#hepr13438-bib-0074){ref-type="ref"}, [75](#hepr13438-bib-0075){ref-type="ref"}

This report presents the results of the 20th Nationwide Follow‐up Survey of Primary Liver Cancer in Japan, with data obtained for 21 075 newly registered patients attending 544 institutions across Japan over the 2‐year period from 1 January 2008 to 31 December 2009. The valid response rate for the 40 769 previously followed patients was 90.4%. Epidemiological, clinicopathological, diagnostic, and treatment‐related data were compiled for newly registered patients. Cumulative survival rates by histological type, background characteristics, and treatments were also calculated for patients newly registered in the 15th to 20th surveys during 1978 to 2009. This special report is a concise version of the original full‐version report published in Japanese.[41](#hepr13438-bib-0041){ref-type="ref"}, [76](#hepr13438-bib-0076){ref-type="ref"}

Methods {#hepr13438-sec-0002}
=======

Basic statistics {#hepr13438-sec-0003}
----------------

The participants of this survey were patients who were hospitalized, underwent outpatient treatment, or underwent autopsy for primary liver cancer at each of 544 collaborating institutions across Japan during the 2‐year period from 1 January 2008 to 31 December 2009, and whose treating institutions had entered patient data for survey items created by the Follow‐up Survey Committee of the Liver Cancer Study Group of Japan (Chair: Masatoshi Kudo) into the National Clinical Database. A total of 21 075 patients were newly registered during this period. When clinical diagnosis, histopathological diagnosis, and histopathological diagnosis determined by autopsy were not consistent, the autopsy result was given precedence when available, and the histopathological diagnosis otherwise. The histological type was hepatocellular carcinoma (HCC) in 94.3% of patients, intrahepatic cholangiocarcinoma (ICC) in 4.8%, and combined hepatocellular cholangiocarcinoma in 0.7% (Table [1](#hepr13438-tbl-0001){ref-type="table"}). The results for patients newly registered in this survey were tabulated. Patients with unknown data for a given parameter were excluded from tabulation for that parameter. The abbreviations used in the table are based on the Fifth Revised Edition of the General Rules for the Clinical and Pathological Study of Primary Liver Cancer.[6](#hepr13438-bib-0006){ref-type="ref"}

###### 

Primary liver cancer diagnosed clinically or histopathologically

+--------------------------------------------+--------+-------+----------------+
| Histological type                          | Men    | Women | Total          |
|                                            |        |       |                |
|                                            |        |       | *n* (%)        |
+:===========================================+:=======+:======+================+
| Hepatocellular carcinoma                   | 13 626 | 6043  | 19 669 (93.33) |
+--------------------------------------------+--------+-------+----------------+
| Intrahepatic cholangiocarcinoma            | 626    | 379   | 1005 (4.77)    |
+--------------------------------------------+--------+-------+----------------+
| Cholangiolocellular carcinoma              | 29     | 13    | 42 (0.20)      |
+--------------------------------------------+--------+-------+----------------+
| Biliary cystadenocarcinoma                 | 14     | 12    | 26 (0.12)      |
+--------------------------------------------+--------+-------+----------------+
| Combined hepatocellular cholangiocarcinoma | 113    | 42    | 155 (0.74)     |
+--------------------------------------------+--------+-------+----------------+
| Hepatoblastoma                             | 6      | 6     | 12 (0.06)      |
+--------------------------------------------+--------+-------+----------------+
| Undifferentiated carcinoma                 | 11     | 5     | 16 (0.08)      |
+--------------------------------------------+--------+-------+----------------+
| Other                                      | 87     | 63    | 150 (0.71)     |
+--------------------------------------------+--------+-------+----------------+
| Total                                      |        |       | 21 075         |
+--------------------------------------------+--------+-------+----------------+

Cumulative survival {#hepr13438-sec-0004}
-------------------

Cumulative survival rates were calculated for HCC, ICC, and combined HCC and ICC by treatments and by background characteristics for patients newly registered between 1998 and 2009 whose final outcome was survival or death (excluding unknown). Cumulative survival rates for HCC were calculated by treatments (hepatectomy, local ablation therapy, and transcatheter arterial chemoembolization \[TACE\]). Cumulative survival rates were also calculated by the registration date by dividing patients newly registered between 1978 and 2009 into four time period groups. These cumulative survival rate calculations were made without censoring any deaths, including those in the "Other" category.

Results {#hepr13438-sec-0005}
=======

Basic statistics {#hepr13438-sec-0006}
----------------

### Causes of death of newly enrolled patients during the survey period {#hepr13438-sec-0007}

The mortality rate during the survey period for newly enrolled patients with HCC was 17.2% (3396 patients). The cause of death was cancer for 62.5%, liver failure for 16.0%, gastrointestinal hemorrhage for 1.4%, and rupture of esophageal or gastric varices for 2.4%. The mortality rate from surgery among the patients who underwent surgery was 0.9% (30 patients). The mortality rate for newly enrolled patients with ICC was 30.0% (302 patients). The cause of death was cancer for 85.4% and liver failure for 4.3% (Table [2](#hepr13438-tbl-0002){ref-type="table"}).

###### 

Prognosis

  ----------------------------------
  ![](HEPR-50-15-g011.jpg "image")
  ----------------------------------

### Past medical history {#hepr13438-sec-0008}

The proportion of patients with a history of chronic hepatitis and cirrhosis was 80.1% for HCC and 22.4% for ICC. The proportion for patients with HCC who had received interferon therapy for chronic hepatitis was 22.1%. For patients with a history of transfusion and excessive alcohol use, the figures were 24.7% and 23.6% for HCC, and 8.1% and 15.3% for ICC, respectively (Table [3](#hepr13438-tbl-0003){ref-type="table"}).

###### 

Past medical history

  ----------------------------------
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  ----------------------------------

For all parameters, *n* is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of *n*.

F0, no fibrosis; F1, fibrous expansion of portal tract; F2, fibrous septa formation, usually incomplete; F3, bridging fibrous formation accompanying lobular distortion A0, no necroinflammatory reaction; A1, mild necroinflammatory reaction; A2, moderate necroinflammatory reaction; A3, severe necroinflammatory reaction; SVR; sustained viral response.

### Clinical diagnosis {#hepr13438-sec-0009}

Mean age of men and women at clinical diagnosis of primary liver cancer was 67.8 and 71.2 years for HCC, and 67.4 and 68.2 years for ICC, respectively. The ratio of male to female patients was 2.26:1 for HCC and 1.68:1 for ICC.

The Child--Pugh grade was A for 76.8%, B for 19.4%, and C for 3.8% of patients (Table [4](#hepr13438-tbl-0004){ref-type="table"}). In HCC, serum α‐fetoprotein was \<15 ng/mL in 46.4%, 15--199 ng/mL in 31.1%, and ≥ 200 ng/mL in 22.5% of patients. lectin‐reactive α‐fetoprotein was \<10% in 68.3%, 10--14.9% in 4.1%, and ≥15% in 27.6% of patients. Protein induced by vitamin K absence or antagonist‐II was \<40 mAU/mL in 39.5%, 40--99 mAU/mL in 15.4%, and ≥100 mAU/mL in 45.1% of patients. In ICC, CEA was \<5.0 ng/mL in 63.5%, 5.0--9.9 ng/mL in 14.8%, and ≥10 ng/mL in 21.7% of patients. CA19--9 was \<37 U/mL in 37.9%, 37--99 U/mL in 13.3%, and ≥ 100 U/mL in 48.8% of patients (Table [4](#hepr13438-tbl-0004){ref-type="table"}).

###### 

Clinical diagnosis

+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
|                                                               | Hepatocellular carcinoma | Intrahepatic cholangiocarcinoma | Combined hepatocellular cholangiocarcinoma |
|                                                               |                          |                                 |                                            |
|                                                               | *n* (%)                  | *n* (%)                         | *n* (%)                                    |
+:==============================================================+==========================+=================================+============================================+
| Evidence for diagnosis                                        | *n* = 33 125             | *n* = 1822                      | *n* = 255                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| CT                                                            | 15 306                   | 822                             | 118                                        |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| MRI                                                           | 4666                     | 324                             | 38                                         |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Ultrasound                                                    | 6889                     | 342                             | 46                                         |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Contrast ultrasound                                           | 822                      | 23                              | 4                                          |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Angiography                                                   | 3984                     | 90                              | 25                                         |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Pathology                                                     | 1213                     | 165                             | 22                                         |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Other                                                         | 245                      | 56                              | 2                                          |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Percentages not calculated as multiple responses were allowed |                          |                                 |                                            |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Performance status                                            | *n* = 17 307             | *n* = 887                       | *n* = 138                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| PS0                                                           | 13 618 (78.7)            | 633 (71.4)                      | 111 (80.4)                                 |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| PS1                                                           | 2685 (15.5)              | 185 (20.9)                      | 16 (11.6)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| PS2                                                           | 616 (3.6)                | 42 (4.7)                        | 9 (6.5)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| PS3                                                           | 274 (1.6)                | 19 (2.1)                        | 2 (1.4)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| PS4                                                           | 114 (0.7)                | 8 (0.9)                         | 0 (0.0)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Encephalopathy                                                | *n* = 18 488             | *n* = 913                       | *n* = 143                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No                                                            | 18 021 (97.5)            | 907 (99.3)                      | 143 (100.0)                                |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Mild                                                          | 359 (1.9)                | 4 (0.4)                         | 0 (0.0)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Moderate‐to‐severe                                            | 108 (0.6)                | 2 (0.2)                         | 0 (0.0)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Ascites                                                       | *n* = 18 863             | *n* = 947                       | *n* = 147                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No                                                            | 16 707 (88.6)            | 878 (92.7)                      | 130 (88.4)                                 |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Responded to treatment                                        | 1434 (7.6)               | 31 (3.3)                        | 8 (5.4)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Refractory to treatment                                       | 722 (3.8)                | 38 (4.0)                        | 9 (6.1)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Serum bilirubin                                               | *n* = 19 053             | *n* = 949                       | *n* = 150                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 0.0--0.9                                                      | 11 422 (59.9)            | 626 (66.0)                      | 100 (66.7)                                 |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 1.0--1.9                                                      | 6097 (32.0)              | 214 (22.6)                      | 42 (28.0)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 2.0--3.0                                                      | 983 (5.2)                | 26 (2.7)                        | 3 (2.0)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥3.1 mg/dL                                                    | 551 (2.9)                | 83 (8.7)                        | 5 (3.3)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Serum albumin                                                 | *n* = 18 997             | *n* = 946                       | *n* = 148                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \<2.8                                                         | 1438 (7.6)               | 52 (5.5)                        | 4 (2.7)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 2.8--2.9                                                      | 878 (4.6)                | 27 (2.9)                        | 5 (3.4)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 3.0--3.5                                                      | 5085 (26.8)              | 146 (15.4)                      | 34 (23.0)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>3.5 g/dL                                                    | 11 596 (61.0)            | 721 (76.2)                      | 105 (70.9)                                 |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ICG R~15~                                                     | *n* = 10 619             | *n* = 622                       | *n* = 106                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤14                                                           | 4508 (42.5)              | 466 (74.9)                      | 65 (61.3)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 15--24                                                        | 3105 (29.2)              | 117 (18.8)                      | 31 (29.2)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 25--40                                                        | 2021 (19.0)              | 35 (5.6)                        | 7 (6.6)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>40%                                                         | 985 (9.3)                | 4 (0.6)                         | 3 (2.8)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Prothrombin activity                                          | *n* = 18 174             | *n* = 877                       | *n* = 148                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \< 40                                                         | 287 (1.6)                | 25 (2.9)                        | 2 (1.4)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 40--49                                                        | 296 (1.6)                | 14 (1.6)                        | 2 (1.4)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 50--70                                                        | 3012 (16.6)              | 65 (7.4)                        | 8 (5.4)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 71--80                                                        | 3641 (20.0)              | 108 (12.3)                      | 28 (18.9)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \> 80%                                                        | 10 938 (60.2)            | 665 (75.8)                      | 108 (73.0)                                 |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Prothrombin time (INR)                                        | *n* = 9175               | *n* = 436                       | *n* = 67                                   |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1.20                                                         | 6840 (74.6)              | 363 (83.3)                      | 59 (88.1)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 1.21--1.30                                                    | 1140 (12.4)              | 37 (8.5)                        | 5 (7.5)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 1.31--1.50                                                    | 826 (9.0)                | 19 (4.4)                        | 2 (3.0)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 1.51--1.80                                                    | 253 (2.8)                | 11 (2.5)                        | 1 (1.5)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥1.81                                                         | 116 (1.3)                | 6 (1.4)                         | 0 (0.0)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Platelets                                                     | *n* = 18 875             | *n* = 942                       | *n* = 150                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \<3.0                                                         | 133 (0.7)                | 2 (0.2)                         | 0 (0.0)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 3.0--4.9                                                      | 807 (4.3)                | 8 (0.8)                         | 5 (3.3)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 5.0--9.9                                                      | 5541 (29.4)              | 54 (5.7)                        | 20 (13.3)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 10.0--14.9                                                    | 5768 (30.6)              | 151 (16.0)                      | 36 (24.0)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 15.0--19.9                                                    | 3513 (18.6)              | 236 (25.1)                      | 42 (28.0)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 20.0--99.9                                                    | 2980 (15.8)              | 479 (50.8)                      | 45 (30.0)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥100 × 10^3^/mm^3^                                            | 133 (0.7)                | 12 (1.3)                        | 2 (1.3)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Liver damage grade by LCSGJ                                   | *n* = 15 137             | *n* = 807                       | *n* = 128                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| A                                                             | 10 388 (68.6)            | 700 (86.7)                      | 96 (75.0)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| B                                                             | 4007 (26.5)              | 77 (9.5)                        | 29 (22.7)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| C                                                             | 742 (4.9)                | 30 (3.7)                        | 3 (2.3)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Child--Pugh grade                                             | *n* = 18 314             | *n* = 890                       | *n* = 145                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| A                                                             | 14 068 (76.8)            | 775 (87.1)                      | 122 (84.1)                                 |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| B                                                             | 3545 (19.4)              | 85 (9.6)                        | 20 (13.8)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| C                                                             | 701 (3.8)                | 30 (3.4)                        | 3 (2.1)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| AFP                                                           | *n* = 18 438             | *n* = 675                       | *n* = 143                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \<15                                                          | 8551 (46.4)              | 571 (84.6)                      | 57 (39.9)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤199                                                          | 5732 (31.1)              | 69 (10.2)                       | 40 (28.0)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤399                                                          | 835 (4.5)                | 12 (1.8)                        | 4 (2.8)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤999                                                          | 912 (4.9)                | 7 (1.0)                         | 15 (10.5)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤9999                                                         | 1390 (7.5)               | 10 (1.5)                        | 21 (14.7)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤99 999                                                       | 670 (3.6)                | 4 (0.6)                         | 5 (3.5)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥100 000 ng/mL                                                | 348 (1.9)                | 2 (0.3)                         | 1 (0.7)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| AFPL~3~                                                       | *n* = 8619               | *n* = 195                       | *n* = 81                                   |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Below detectable levels                                       | 3063 (35.5)              | 124 (63.6)                      | 25 (30.9)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \<5.0                                                         | 2129 (24.7)              | 30 (15.4)                       | 14 (17.3)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤9.9                                                          | 699 (8.1)                | 7 (3.6)                         | 6 (7.4)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤14.9                                                         | 354 (4.1)                | 2 (1.0)                         | 2 (2.5)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤19.9                                                         | 256 (3.0)                | 3 (1.5)                         | 1 (1.2)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥20.0%                                                        | 2118 (24.6)              | 29 (14.9)                       | 33 (40.7)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| PIVKA‐II                                                      | *n* = 17 540             | *n* = 565                       | *n* = 137                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \<40                                                          | 6927 (39.5)              | 449 (79.5)                      | 61 (44.5)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤99                                                           | 2700 (15.4)              | 46 (8.1)                        | 12 (8.8)                                   |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤299                                                          | 2303 (13.1)              | 26 (4.6)                        | 17 (12.4)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤499                                                          | 823 (4.7)                | 4 (0.7)                         | 5 (3.6)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤999                                                          | 919 (5.2)                | 4 (0.7)                         | 6 (4.4)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤2999                                                         | 1237 (7.1)               | 14 (2.5)                        | 16 (11.7)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤9999                                                         | 1036 (5.9)               | 7 (1.2)                         | 8 (5.8)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥10 000 mAU/mL                                                | 1595 (9.1)               | 15 (2.7)                        | 12 (8.8)                                   |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| CEA                                                           | *n* = 7294               | *n* = 858                       | *n* = 117                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \<2.5                                                         | 2803 (38.4)              | 295 (34.4)                      | 53 (45.3)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤4.9                                                          | 2826 (38.7)              | 250 (29.1)                      | 31 (26.5)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤9.9                                                          | 1351 (18.5)              | 127 (14.8)                      | 17 (14.5)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤19.9                                                         | 215 (2.9)                | 60 (7.0)                        | 5 (4.3)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤49.9                                                         | 55 (0.8)                 | 47 (5.5)                        | 4 (3.4)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤99.9                                                         | 17 (0.2)                 | 26 (3.0)                        | 1 (0.9)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥100 ng/mL                                                    | 27 (0.4)                 | 53 (6.2)                        | 6 (5.1)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| CA19--9                                                       | *n* = 6311               | *n* = 837                       | *n* = 109                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \<37                                                          | 4541 (72.0)              | 317 (37.9)                      | 54 (49.5)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤99                                                           | 1303 (20.6)              | 111 (13.3)                      | 24 (22.0)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤299                                                          | 338 (5.4)                | 110 (13.1)                      | 11 (10.1)                                  |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤999                                                          | 78 (1.2)                 | 80 (9.6)                        | 7 (6.4)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤2999                                                         | 28 (0.4)                 | 76 (9.1)                        | 9 (8.3)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤9999                                                         | 8 (0.1)                  | 59 (7.0)                        | 2 (1.8)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥10 000 U/mL                                                  | 15 (0.2)                 | 84 (10.0)                       | 2 (1.8)                                    |
+---------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+

For all parameters, *n* is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of *n*.

AFP, α‐fetoprotein; AFPL~3~, lectin‐reactive α‐fetoprotein; CA 19--9, carbohydrate antigen 19--9; CEA, carcinoembryonic antigen; ICG R15, indocyanine green retention rate at 15 min; INR, international normalized ratio; LCSGJ, Liver Cancer Study Group of Japan; PIVKA‐II, protein induced by vitamin K absence or antagonist‐II.

The hepatitis B surface antigen‐positive rate was 15.2% for HCC, 8.2% for ICC, and 16.3% for combined HCC and ICC. The hepatitis C virus antibody‐positive rate was 60.7% for HCC, 14.9% for ICC, and 35.3% for combined HCC and ICC (Table [5](#hepr13438-tbl-0005){ref-type="table"}).

###### 

Hepatitis B virus antigen/antibody and hepatitis C virus antibody

+------------------+--------------------------+---------------------------------+--------------------------------------------+
|                  | Hepatocellular carcinoma | Intrahepatic cholangiocarcinoma | Combined hepatocellular cholangiocarcinoma |
|                  |                          |                                 |                                            |
|                  | *n* (%)                  | *n* (%)                         | *n* (%)                                    |
+:=================+==========================+=================================+============================================+
| HBsAg            | *n* = 18 219             | *n* = 934                       | *n* = 147                                  |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Negative         | 15 449 (84.8)            | 857 (91.8)                      | 123 (83.7)                                 |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Positive         | 2768 (15.2)              | 77 (8.2)                        | 24 (16.3)                                  |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Equivocal        | 2 (0.0)                  | 0 (0.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| HBsAb            | *n* = 5670               | *n* = 251                       | *n* = 45                                   |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Negative         | 4362 (76.9)              | 190 (75.7)                      | 34 (75.6)                                  |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Positive         | 1267 (22.3)              | 61 (24.3)                       | 10 (22.2)                                  |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Equivocal        | 41 (0.7)                 | 0 (0.0)                         | 1 (2.2)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| HBcAb            | *n* = 6033               | *n* = 229                       | *n* = 62                                   |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Negative         | 2850 (47.2)              | 129 (56.3)                      | 33 (53.2)                                  |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Positive         | 3141 (52.1)              | 100 (43.7)                      | 29 (46.8)                                  |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Equivocal        | 42 (0.7)                 | 0 (0.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| HBeAg            | *n* = 4030               | *n* = 152                       | *n* = 42                                   |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Negative         | 3456 (85.8)              | 141 (92.8)                      | 39 (92.9)                                  |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Positive         | 569 (14.1)               | 11 (7.2)                        | 3 (7.1)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Equivocal        | 5 (0.1)                  | 0 (0.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| HBeAb            | *n* = 4006               | *n* = 151                       | *n* = 46                                   |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Negative         | 2155 (53.8)              | 90 (59.6)                       | 22 (47.8)                                  |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Positive         | 1837 (45.9)              | 61 (40.4)                       | 24 (52.2)                                  |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Equivocal        | 14 (0.3)                 | 0 (0.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| HBV‐DNA load     | *n* = 1379               | *n* = 20                        | *n* = 9                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| \<3.7 LGE        | 65 (4.7)                 | 0 (0.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 3.7--3.9 LGE     | 24 (1.7)                 | 0 (0.0)                         | 0 (0.0                                     |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 4.0--4.9 LGE     | 39 (2.8)                 | 0 (0.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 5.0--5.9 LGE     | 27 (2.0)                 | 0 (0.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 6.0--6.9 LGE     | 34 (2.5)                 | 0 (0.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 7.0--7.9 LGE     | 25 (1.8)                 | 0 (0.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 8.0--8.7 LGE     | 9 (0.7)                  | 0 (0.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>8.7 LGE        | 2 (0.1)                  | 0 (0.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| \<2.1 Logcopy    | 90 (6.5)                 | 2 (10.0)                        | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 2.1--2.9 Logcopy | 269 (19.5)               | 7 (35.0)                        | 1 (11.1)                                   |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 3.0--3.9 Logcopy | 176 (12.8)               | 3 (15.0)                        | 3 (33.3)                                   |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 4.0--4.9 Logcopy | 145 (10.5)               | 1 (5.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 5.0--5.9 Logcopy | 131 (9.5)                | 2 (10.0)                        | 1 (11.1)                                   |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 6.0--6.9 Logcopy | 201 (14.6)               | 3 (15.0)                        | 3 (33.3                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 7.0--7.9 Logcopy | 114 (8.3)                | 2 (10.0)                        | 1 (11.1)                                   |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 8.0--8.8 Logcopy | 26 (1.9)                 | 0 (0.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>8.8 Logcopy    | 2 (0.1)                  | 0 (0.0)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| HCV‐Ab           | *n* = 18 097             | *n* = 931                       | *n* = 13                                   |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Negative         | 7094 (39.2)              | 790 (84.9)                      | 86 (64.7)                                  |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Positive         | 10 976 (60.7)            | 139 (14.9)                      | 47 (35.3)                                  |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Equivocal        | 27 (0.1)                 | 2 (0.2)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| HCV‐RNA          | *n* = 3761               | *n* = 69                        | *n* = 22                                   |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| Negative         | 885 (23.5)               | 38 (55.1)                       | 10 (45.5)                                  |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| \<1.2            | 41 (1.1)                 | 1 (1.4)                         | 0 (0.0)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 1.2--2.9         | 98 (2.6)                 | 1 (1.4)                         | 2 (9.1)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 3.0--4.9         | 428 (11.4)               | 5 (7.2)                         | 2 (9.1)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 5.0--6.9         | 2006 (53.3)              | 18 (26.1)                       | 6 (27.3)                                   |
+------------------+--------------------------+---------------------------------+--------------------------------------------+
| 7.0-- logIU/mL   | 303 (8.1)                | 6 (8.7)                         | 2 (9.1)                                    |
+------------------+--------------------------+---------------------------------+--------------------------------------------+

For all parameters, *n* is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of *n*.

HBcAb, antibody to hepatitis B core antigen; HBeAb, antibody to hepatitis B e antigen; HBeAg, hepatitis B e antigen; HBsAb, antibody to hepatitis B surface antigen; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus.

Tumor diameter on imaging at diagnosis was ≤2 cm in 34.4% and 2.1--5.0 cm in 43.7% of patients with HCC. For ICC, these figures were 13.7% and 47.2%. The proportion of patients with unifocal disease was 61.3% for HCC and 74.8% for ICC (Table [6](#hepr13438-tbl-0006){ref-type="table"}). Tumor staining was observed in 93.1%, tumor rupture in 0.9%, and F2 or larger/red color sign (+) esophageal or gastric varices in 35.8% of patients.

###### 

Imaging diagnosis

+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
|                                                           | Hepatocellular carcinoma | Intrahepatic cholangiocarcinoma | Combined hepatocellular cholangiocarcinoma |
|                                                           |                          |                                 |                                            |
|                                                           | *n* (%)                  | *n* (%)                         | *n* (%)                                    |
+:==========================================================+==========================+=================================+============================================+
| Maximum diameter of primary tumor                         | *n* = 18 524             | *n* = 901                       | *n* = 142                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1 cm                                                     | 995 (5.4)                | 22 (2.4)                        | 1 (0.7)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>1 cm to ≤2 cm                                           | 5367 (29.0)              | 102 (11.3)                      | 13 (9.2)                                   |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>2 cm to ≤3 cm                                           | 4354 (23.5)              | 179 (19.9)                      | 27 (19.0)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>3 cm to ≤5 cm                                           | 3733 (20.2)              | 246 (27.3)                      | 41 (28.9)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>5 cm to ≤10 cm                                          | 2841 (15.3)              | 279 (31.0)                      | 42 (29.6)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>10 cm to ≤15 cm                                         | 898 (4.8)                | 60 (6.7)                        | 14 (9.9)                                   |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>15 cm to ≤20 cm                                         | 232 (1.3)                | 12 (1.3)                        | 4 (2.8)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>20 cm to ≤25 cm                                         | 73 (0.4)                 | 1 (0.1)                         | 0 (0.0)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>25 cm                                                   | 31 (0.2)                 | 0 (0.0)                         | 0 (0.0)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No. tumors                                                | *n* = 18 629             | *n* = 923                       | *n* = 139                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 1                                                         | 11 424 (61.3)            | 690 (74.8)                      | 84 (60.4)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 2                                                         | 3150 (16.9)              | 69 (7.5)                        | 20 (14.4)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 3                                                         | 1236 (6.6)               | 27 (2.9)                        | 7 (5.0)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 4                                                         | 524 (2.8)                | 18 (2.0)                        | 3 (2.2)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 5                                                         | 276 (1.5)                | 4 (0.4)                         | 2 (1.4)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥6                                                        | 2019 (10.8)              | 115 (12.5)                      | 23 (16.5)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Multifocal disease                                        | *n* = 14 184             | *n* = 669                       | *n* = 121                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Single lobe                                               | 10 222 (72.1)            | 534 (79.8)                      | 89 (73.6)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Both lobes                                                | 3962 (27.9)              | 135 (20.2)                      | 32 (26.4)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hepatocellular carcinoma                                  | *n* = 17 276             |                                 |                                            |
|                                                           |                          |                                 |                                            |
| Morphological classification of primary tumor on imaging  |                          |                                 |                                            |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Nodular                                                   | 15 307 (88.6)            |                                 |                                            |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Massive                                                   | 1308 (7.6)               |                                 |                                            |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Diffuse                                                   | 599 (3.5)                |                                 |                                            |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Other                                                     | 62 (0.4)                 |                                 |                                            |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Arterial phase enhancement                                | *n* = 17 642             | *n* = 823                       | *n* = 135                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No                                                        | 1214 (6.9)               | 440 (53.5)                      | 16 (11.9)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Yes                                                       | 16 428 (93.1)            | 383 (46.5)                      | 119 (88.1)                                 |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Venous phase washout                                      | *n* = 16 180             | *n* = 729                       | *n* = 113                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No                                                        | 1489 (9.2)               | 543 (74.5)                      | 26 (23.0)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Yes                                                       | 14 691 (90.8)            | 186 (25.5)                      | 87 (77.0)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Internal component of tumor                               | *n* = 16 941             | *n* = 761                       | *n* = 137                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Solid                                                     | 16 793 (99.1)            | 738 (97.0)                      | 136 (99.3)                                 |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Cystic                                                    | 148 (0.9)                | 23 (3.0)                        | 1 (0.7)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Portal vein invasion by imaging                           | *n* = 17 855             | *n* = 854                       | *n* = 137                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vp~0~                                                     | 15 669 (87.8)            | 580 (67.9)                      | 97 (70.8)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vp~1~                                                     | 579 (3.2)                | 61 (7.1)                        | 10 (7.3)                                   |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vp~2~                                                     | 463 (2.6)                | 78 (9.1)                        | 9 (6.6)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vp~3~                                                     | 616 (3.5)                | 102 (11.9)                      | 15 (10.9)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vp~4~                                                     | 528 (3.0)                | 33 (3.9)                        | 6 (4.4)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hepatic vein invasion by imaging                          | *n* = 17 263             | *n* = 808                       | *n* = 133                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vv~0~                                                     | 16 401 (95.0)            | 683 (84.5)                      | 119 (89.5)                                 |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vv~1~                                                     | 305 (1.8)                | 45 (5.6)                        | 6 (4.5)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vv~2~                                                     | 295 (1.7)                | 60 (7.4)                        | 4 (3.0)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vv~3~                                                     | 262 (1.5)                | 20 (2.5)                        | 4 (3.0)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Bile duct invasion by imaging                             | *n* = 17 039             | *n* = 801                       | *n* = 133                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| B~0~                                                      | 16 569 (97.2)            | 488 (60.9)                      | 113 (85.0)                                 |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| B~1~                                                      | 195 (1.1)                | 76 (9.5)                        | 6 (4.5)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| B~2~                                                      | 121 (0.7)                | 99 (12.4)                       | 6 (4.5)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| B~3~                                                      | 96 (0.6)                 | 91 (11.4)                       | 5 (3.8)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| B~4~                                                      | 58 (0.3)                 | 47 (5.9)                        | 3 (2.3)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Tumor rupture                                             | *n* = 18 337             | *n* = 759                       | *n* = 144                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No rupture                                                | 17 853 (97.4)            | 753 (99.2)                      | 144 (100.0)                                |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Suspected rupture                                         | 316 (1.7)                | 3 (0.4)                         | 0 (0.0)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Rupture                                                   | 168 (0.9)                | 3 (0.4)                         | 0 (0.0)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Extrahepatic spread                                       | *n* = 1091               | *n* = 264                       | *n* = 41                                   |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Lung                                                      | 319                      | 48                              | 6                                          |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Bone                                                      | 204                      | 22                              | 2                                          |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Adrenal gland                                             | 67                       | 6                               | 2                                          |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Lymph node                                                | 410                      | 148                             | 27                                         |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Brain                                                     | 11                       | 1                               | 0                                          |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Peritoneum                                                | 44                       | 21                              | 3                                          |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Other                                                     | 36                       | 18                              | 1                                          |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Percentages not calculated as multiple sites were allowed |                          |                                 |                                            |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Esophageal/gastric varices                                | *n* = 4195               | *n* = 30                        | *n* = 15                                   |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤F1, RC (−)                                               | 2428 (57.9)              | 21 (70.0)                       | 9 (60.0)                                   |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥F2, RC (+)                                               | 1503 (35.8)              | 8 (26.7)                        | 5 (33.3)                                   |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Rupture                                                   | 264 (6.3)                | 1 (3.3)                         | 1 (6.7)                                    |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| TNM Stage by LCSGJ                                        | *n* = 18 207             | *n* = 882                       | *n* = 138                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Stage I                                                   | 4583 (25.2)              | 78 (8.8)                        | 24 (17.4)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Stage II                                                  | 7280 (40.0)              | 268 (30.4)                      | 36 (26.1)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Stage III                                                 | 4162 (22.9)              | 206 (23.4)                      | 32 (23.2)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Stage IVA                                                 | 1504 (8.3)               | 118 (13.4)                      | 21 (15.2)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Stage IVB                                                 | 678 (3.7)                | 212 (24.0)                      | 25 (18.1)                                  |
+-----------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+

For all parameters, *n* is the total number of patients excluding those in the "unknown" category, and (%) is the percentage of *n*.

B~0~, absence of invasion of the bile ducts; B~1~, invasion of (or tumor thrombus in) the third order or more peripheral branches of the bile duct, but not of second order branches; B~2~, invasion of (or tumor thrombus in) the second order branches of the bile duct; B~3~, invasion of (or tumor thrombus in) the first order branches of the bile duct; B~4~, invasion of (or tumor thrombus in) the common hepatic duct.; F1, small varices; F2, moderate varices; RC, red color sign; Vp0, absence of invasion of (or tumor thrombus in) the portal vein; Vp~1~, invasion of (or tumor thrombus in) distal to the second order branches of the portal vein, but not of the second order branches; Vp~2~, invasion of (or tumor thrombus in) second order branches of the portal vein; Vp~3~, invasion of (or tumor thrombus in) first order branches of the portal vein; Vp~4~, invasion of (or tumor thrombus in) the main trunk of the portal vein and/or contra‐lateral portal vein branch to the primarily involved lobe; Vv~0~, absence of invasion of (or tumor thrombus in) the hepatic vein; Vv~1~, invasion of (or tumor thrombus in) peripheral branches of the hepatic vein; Vv~2~, invasion of (or tumor thrombus in) the right, middle, or left hepatic vein, the inferior right hepatic vein, or the short hepatic vein; Vv~3~, invasion of (or tumor thrombus in) the inferior vena cava.

### Initial treatments {#hepr13438-sec-0010}

The initial treatment method for HCC was surgical intervention (resection or transplantation) in 37.7%, local ablation therapy in 28.4%, and TACE in 27.5% of patients. For ICC, these figures were 72.9% for surgery (resection only) and 16.6% for systemic chemotherapy, and for combined HCC and ICC, they were 71.8% for surgery (hepatectomy only) and 4.2% for systemic chemotherapy (Table [7](#hepr13438-tbl-0007){ref-type="table"}). The distribution of Child--Pugh grades (A/B/C) was 78.4%/20.3%/1.3% for those who underwent surgery, 69.2%/27.4%/3.3% for those who underwent local ablation therapy, and 59.7%/35.8%/4.4% for those who underwent TACE.

###### 

Initial treatment

+------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
|                                          | Hepatocellular carcinoma | Intrahepatic cholangiocarcinoma | Combined hepatocellular cholangiocarcinoma |
|                                          |                          |                                 |                                            |
|                                          | *n* (%)                  | *n* (%)                         | *n* (%)                                    |
+:=========================================+==========================+=================================+============================================+
|                                          | *n* = 18 458             | *n* = 872                       | *n* = 142                                  |
+------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Surgery                                  | 6960 (37.7)              | 636 (72.9)                      | 102 (71.8)                                 |
+------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Local ablation therapy                   | 5249 (28.4)              | 31 (3.6)                        | 5 (3.5)                                    |
+------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Transcatheter arterial chemoembolization | 5083 (27.5)              | 15 (1.7)                        | 16 (11.3)                                  |
+------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hepatic arterial infusion chemotherapy   | 829 (4.5)                | 25 (2.9)                        | 11 (7.7)                                   |
+------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Systemic chemotherapy                    | 166 (0.9)                | 145 (16.6)                      | 6 (4.2)                                    |
+------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Other therapy                            | 171 (0.9)                | 20 (2.3)                        | 2 (1.4)                                    |
+------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No therapy (BSC)                         | 1099                     | 118                             | 11                                         |
+------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+

BSC. best supportive care.

### Surgery {#hepr13438-sec-0011}

A total of 6940 patients with HCC underwent hepatectomy and 122 underwent liver transplantation. The most common macroscopic classification of resected specimens was simple nodular type for HCC at 59.9% and mass‐forming type for ICC at 76.4% (Tables [8](#hepr13438-tbl-0008){ref-type="table"}, [9](#hepr13438-tbl-0009){ref-type="table"}).

###### 

Macroscopic classification of hepatocellular carcinoma

  Macroscopic classification                     Hepatocellular carcinoma                                
  ---------------------------------------------- -------------------------- -------- ---------- -------- ------
                                                 *n* = 4961                          *n* = 71            5032
  Small nodular type with indistinct margin      95                         (1.9)    1          (1.4)    96
  Simple nodular type                            2970                       (59.9)   55         (77.5)   3025
  Simple nodular type with extranodular growth   1039                       (20.9)   5          (7.0)    1044
  Confluent multinodular type                    793                        (16.0)   10         (14.1)   803
  Infiltrative type                              64                         (1.3)    0          (0.0)    64

###### 

Macroscopic classification of intrahepatic cholangiocarcinoma

  Macroscopic classification                                        Intrahepatic cholangiocarcinoma   
  ----------------------------------------------------------------- --------------------------------- --------
                                                                    *n* = 521                         
  Mass‐forming type                                                 398                               (76.4)
  Periductal infiltrating type                                      23                                (4.4)
  Intraductal growth type                                           14                                (2.7)
  Mix of mass‐forming type and periductal infiltrating type         71                                (13.6)
  Mix of periductal infiltrating type and intraductal growth type   6                                 (1.2)
  Mix of mass‐forming type and intraductal growth type              8                                 (1.5)
  Other                                                             1                                 (0.2)

Tumor diameter among patients who underwent hepatectomy for HCC was ≤2 cm in 20.0%, 2--5 cm in 52.0%, and 5--10 cm in 20.3%. The percentage with unifocal disease was 75.9%. Vascular invasion was observed in the portal vein in 16.1%, hepatic veins in 6.8%, and bile duct in 2.8% of patients. The non‐cancerous part of the liver was normal in 10.6%, showed chronic hepatitis or fibrosis in 50.9%, and showed cirrhosis in 38.4% of patients. The type of surgery was Hr0 (limited resection) in 28.0%, HrS (1 subsegmentectomy) in 25.1%, Hr1 (1 segmentectomy) in 24.1%, Hr2 (2 segmentectomy) in 20.6%, and Hr3 (3 segmentectomy) in 2.2% of patients (Table [10](#hepr13438-tbl-0010){ref-type="table"}).

###### 

Macroscopic findings in resected specimen and surgery‐related factors

+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
|                                            | Hepatocellular carcinoma | Intrahepatic cholangiocarcinoma | Combined hepatocellular cholangiocarcinoma |
|                                            |                          |                                 |                                            |
|                                            | *n* (%)                  | *n* (%)                         | *n* (%)                                    |
+:===========================================+==========================+=================================+============================================+
| Maximum diameter of resected primary tumor | *n* = 6586               | *n* = 597                       | *n* = 100                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1 cm                                      | 169 (2.6)                | 6 (1.0)                         | 1 (1.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>1 cm to ≤2 cm                            | 1143 (17.4)              | 69 (11.6)                       | 11 (11.0)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>2 cm to ≤3 cm                            | 1619 (24.6)              | 125 (20.9)                      | 25 (25.0)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>3 cm to ≤5 cm                            | 1806 (27.4)              | 194 (32.5)                      | 30 (30.0)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>5 cm to ≤10 cm                           | 1339 (20.3)              | 168 (28.1)                      | 27 (27.0)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>10 cm to ≤15 cm                          | 380 (5.8)                | 30 (5.0)                        | 5 (5.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>15 cm to ≤20 cm                          | 98 (1.5)                 | 5 (0.8)                         | 1 (1.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>20 cm to ≤25 cm                          | 24 (0.4)                 | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>25 cm                                    | 8 (0.1)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No. tumors resected                        | *n* = 6616               | *n* = 609                       | *n* = 98                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 1                                          | 5021 (75.9)              | 517 (84.9)                      | 72 (73.5)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 2                                          | 907 (13.7)               | 42 (6.9)                        | 12 (12.2)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 3                                          | 272 (4.1)                | 13 (2.1)                        | 6 (6.1)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 4                                          | 112 (1.7)                | 10 (1.6)                        | 2 (2.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 5                                          | 57 (0.9)                 | 3 (0.5)                         | 1 (1.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥ 6                                        | 247 (3.7)                | 24 (3.9)                        | 5 (5.1)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Tumor distribution^1^                      | *n* = 6456               | *n* = 591                       | *n* = 97                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| H~S~                                       | 2648 (41.0)              | 123 (20.8)                      | 37 (38.1)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| H~1~                                       | 1877 (29.1)              | 182 (30.8)                      | 23 (23.7)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| H~2~                                       | 1514 (23.5)              | 240 (40.6)                      | 23 (23.7)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| H~3~                                       | 309 (4.8)                | 33 (5.6)                        | 10 (10.3)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| H~4~                                       | 108 (1.7)                | 13 (2.2)                        | 4 (4.1)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Tumor distribution^2^                      | *n* = 6383               | *n* = 589                       | *n* = 96                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Localized to one lobe                      | 5582 (87.5)              | 517 (87.8)                      | 78 (81.3)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Both lobes                                 | 801 (12.5)               | 72 (12.2)                       | 18 (18.8)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Growth pattern                             | *n* = 6288               | *n* = 536                       | *n* = 92                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Eg                                         | 5843 (92.9)              | 267 (49.8)                      | 67 (72.8)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Ig                                         | 445 (7.1)                | 269 (50.2)                      | 25 (27.2)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Capsule formation                          | *n* = 6317               | *n* = 540                       | *n* = 94                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Fc (−)                                     | 1477 (23.4)              | 474 (87.8)                      | 48 (51.1)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Fc (+)                                     | 4840 (76.6)              | 66 (12.2)                       | 46 (48.9)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Capsule invasion                           | *n* = 4718               | *n* = 66                        | *n* = 43                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Fc‐Inf (−)                                 | 2385 (50.6)              | 30 (45.5)                       | 20 (46.5)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Fc‐Inf (+)                                 | 2333 (49.4)              | 36 (54.5)                       | 23 (53.5)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Septum formation                           | *n* = 6037               | *n* = 530                       | *n* = 79                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Sf (−)                                     | 2682 (44.4)              | 477 (90.0)                      | 43 (54.4)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Sf (+)                                     | 3355 (55.6)              | 53 (10.0)                       | 36 (45.6)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Serosal invasion                           | *n* = 6307               | *n* = 552                       | *n* = 92                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| S~0~ (no serosal invasion)                 | 5398 (85.6)              | 363 (65.8)                      | 68 (73.9)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| S~1~ (invasion +)                          | 697 (11.1)               | 138 (25.0)                      | 18 (19.6)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| S~2~ (invasion to adjacent organ)          | 110 (1.7)                | 47 (8.5)                        | 4 (4.3)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| S~3~ (intraperitoneal rupture)             | 102 (1.6)                | 4 (0.7)                         | 2 (2.2)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Lymph node metastasis                      | *n* = 6234               | *n* = 581                       | *n* = 91                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| N~0~                                       | 6172 (99.0)              | 434 (74.7)                      | 81 (89.0)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| N~1~                                       | 62 (1.0)                 | 147 (25.3)                      | 10 (11.0)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Portal vein invasion                       | *n* = 6468               | *n* = 586                       | *n* = 97                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vp~0~                                      | 5429 (83.9)              | 378 (64.5)                      | 68 (70.1)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vp~1~                                      | 618 (9.6)                | 90 (15.4)                       | 16 (16.5)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vp~2~                                      | 188 (2.9)                | 58 (9.9)                        | 8 (8.2)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vp~3~                                      | 158 (2.4)                | 51 (8.7)                        | 5 (5.2)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vp~4~                                      | 75 (1.2)                 | 9 (1.5)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hepatic vein invasion                      | *n* = 6463               | *n* = 580                       | *n* = 97                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vv~0~                                      | 6022 (93.2)              | 457 (78.8)                      | 88 (90.7)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vv~1~                                      | 289 (4.5)                | 72 (12.4)                       | 7 (7.2)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vv~2~                                      | 96 (1.5)                 | 42 (7.2)                        | 2 (2.1)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Vv~3~                                      | 56 (0.9)                 | 9 (1.6)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hepatic artery invasion                    | *n* = 6191               | *n* = 543                       | n = 83                                     |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Va~0~                                      | 6132 (99.0)              | 483 (89.0)                      | 81 (97.6)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Va~1~                                      | 46 (0.7)                 | 28 (5.2)                        | 2 (2.4)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Va~2~                                      | 13 (0.2)                 | 18 (3.3)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Va~3~                                      | 0 (0.0)                  | 14 (2.6)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Bile duct invasion                         | *n* = 6440               | *n* = 567                       | *n* = 95                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| B~0~                                       | 6258 (97.2)              | 296 (52.2)                      | 87 (91.6)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| B~1~                                       | 89 (1.4)                 | 83 (14.6)                       | 5 (5.3)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| B~2~                                       | 40 (0.6)                 | 78 (13.8)                       | 1 (1.1)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| B~3~                                       | 38 (0.6)                 | 74 (13.1)                       | 1 (1.1)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| B~4~                                       | 15 (0.2)                 | 36 (6.3)                        | 1 (1.1)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Intrahepatic metastasis                    | *n* = 6228               | *n* = 561                       | *n* = 93                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| IM~0~ (no metastasis)                      | 5375 (86.3)              | 483 (86.1)                      | 76 (81.7)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| IM~S~ (within subsegment)                  | 167 (2.7)                | 14 (2.5)                        | 3 (3.2)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| IM~1~ (within 1 segment)                   | 314 (5.0)                | 31 (5.5)                        | 7 (7.5)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| IM~2~ (within 2 segment)                   | 249 (4.0)                | 23 (4.1)                        | 2 (2.2)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| IM~3~ (within 3 segment)                   | 123 (2.0)                | 10 (1.8)                        | 5 (5.4)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Peritoneal metastasis                      | *n* = 6417               | *n* = 597                       | *n* = 97                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| P~0~ (no metastasis)                       | 6382 (99.5)              | 584 (97.8)                      | 97 (100.0)                                 |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| P~1~ (proximal peritoneum)                 | 27 (0.4)                 | 9 (1.5)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| P~2~ (distal peritoneum)                   | 8 (0.1)                  | 4 (0.7)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Invasion of surgical margin                | *n* = 6298               | *n* = 568                       | *n* = 93                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| SM (+) with exposure of cancer             | 298 (4.7)                | 51 (9.0)                        | 9 (9.7)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| SM (−) 0 mm                                | 693 (11.0)               | 47 (8.3)                        | 8 (8.6)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| SM (−) ≤5 mm                               | 1255 (19.9)              | 91 (16.0)                       | 16 (17.2)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| SM (−) ≤10 mm                              | 676 (10.7)               | 53 (9.3)                        | 9 (9.7)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| SM (−) \>10 mm                             | 548 (8.7)                | 57 (10.0)                       | 3 (3.2)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| SM (−) distance unknown                    | 2828 (44.9)              | 269 (47.4)                      | 48 (51.6)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Findings in non‐cancerous liver parenchyma | *n* = 6237               | *n* = 549                       | *n* = 89                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Normal liver                               | 664 (10.6)               | 366 (66.7)                      | 13 (14.6)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Chronic hepatitis, liver fibrosis          | 3177 (50.9)              | 132 (24.0)                      | 48 (53.9)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Liver cirrhosis                            | 2396 (38.4)              | 51 (9.3)                        | 28 (31.5)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hepatectomy                                | *n* = 6296               | *n* = 594                       | *n* = 97                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hr0 (\<subsegmentectomy)                   | 1766 (28.0)              | 54 (9.1)                        | 16 (16.5)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| HrS (\<1 segmentectomy)                    | 1579 (25.1)              | 58 (9.8)                        | 26 (26.8)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hr1 (1segmentectomy)                       | 1515 (24.1)              | 97 (16.3)                       | 19 (19.6)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hr2 (2 segmentectomy)                      | 1297 (20.6)              | 338 (56.9)                      | 28 (28.9)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hr3 (3 segmentectomy)                      | 138 (2.2)                | 46 (7.7)                        | 8 (8.2)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Total hepatectomy                          | 1 (0.0)                  | 1 (0.2)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Lymph node dissection                      | *n* = 6116               | *n* = 575                       | *n* = 89                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| D (−)                                      | 5983 (97.8)              | 285 (49.6)                      | 76 (85.4)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| D (+)                                      | 133 (2.2)                | 290 (50.4)                      | 13 (14.6)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Residual cancer                            | *n* = 6277               | *n* = 587                       | *n* = 93                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No                                         | 6006 (95.7)              | 557 (94.9)                      | 87 (93.5)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Yes                                        | 271 (4.3)                | 30 (5.1)                        | 6 (6.5)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Extrahepatic metastasis                    | *n* = 6299               | *n* = 605                       | *n* = 86                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| M~0~                                       | 6227 (98.9)              | 583 (96.4)                      | 84 (97.7)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| M~1~                                       | 72 (1.1)                 | 22 (3.6)                        | 2 (2.3)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| TNM stage by LCSGJ                         | *n* = 6407               | *n* = 590                       | *n* = 82                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Stage I                                    | 945 (14.7)               | 33 (5.6)                        | 8 (9.8)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Stage II                                   | 3294 (51.4)              | 197 (33.4)                      | 30 (36.6)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Stage III                                  | 1534 (23.9)              | 171 (29.0)                      | 30 (36.6)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Stage IVA                                  | 543 (8.5)                | 67 (11.4)                       | 10 (12.2)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Stage IVB                                  | 91 (1.4)                 | 122 (20.7)                      | 4 (4.9)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+

For all parameters, *n* is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of *n*.

B~0~, absence of invasion of the bile ducts; B~1~, invasion of (or tumor thrombus in) the third order or more peripheral branches of the bile duct, but not of second order branches; B~2~, invasion of (or tumor thrombus in) the second order branches of the bile duct; B~3~, invasion of (or tumor thrombus in) the first order branches of the bile duct; B~4~, invasion of (or tumor thrombus in) the common hepatic duct; Eg, expansive growth, well‐demarcated border; Fc (−), absence of capsule formation; Fc (+), presence of capsule formation; Fc‐Inf (−), absence of cancerous infiltration of the tumor capsule; Fc‐Inf (+), presence of cancerous infiltration of the tumor capsule; H1, cancer limited to one segment; H2, cancer limited to two segments; H3, cancer limited to three segments; H4, cancer involving more than three segments; Hr0, resection of less than one subsegment (Couinaud\'s segment); HrS, resection of one subsegment (Couinaud\'s segment); Hr1, resection of one segment (anterior, posterior, medial, or left lateral segmentectomy); Hr2, resection of two segments (right or left bisegmentectomy or central bisegmentectomy); Hr3, resection of three segments (right or left trisegmentectomy); Hs, cancer limited to one subsegment, poorly demarcated border; Ig, infiltrative growth; IM~0~, absence of intrahepatic metastasis; IM~1~, intrahepatic metastasis within the subsegment in which the principal tumor is located; IM~2~, intrahepatic metastasis in two segments; IM~3~, intrahepatic metastasis to three or more segments; IM~s~, intrahepatic metastasis within the subsegment in which the principal tumor is located; LCSGJ, Liver Cancer Study Group of Japan; S0, absence of invasion of the serosa; S1, tumor invasion of the serosa; S2, tumor invasion of adjacent organs; S3, tumor rupture with intraperitoneal bleeding; Sf (−), absence of formation of a fibrous septum within the tumor; Sf (+), presence of fibrous septum within the tumor; TNM, tumor--node--metastasis; Va~0~, absence of invasion of the hepatic artery; Va~1~, invasion distal to the second order branches of the hepatic artery, but not of the second order branches; Va~2~, invasion to the second order branches of the hepatic artery; Va~3~, invasion to the left or right hepatic artery, or the proper hepatic artery; Vp~0~, absence of invasion of (or tumor thrombus in) the portal vein; Vp~1~, invasion of (or tumor thrombus in) distal to the second order branches of the portal vein, but not of the second order branches; Vp~2~, invasion of (or tumor thrombus in) second order branches of the portal vein; Vp~3~, invasion of (or tumor thrombus in) first order branches of the portal vein; Vp~4~, invasion of (or tumor thrombus in) the main trunk of the portal vein and/or contra‐lateral portal vein branch to the primarily involved lobe; Vv~0~, absence of invasion of (or tumor thrombus in) the hepatic vein; Vv~1~, invasion of (or tumor thrombus in) peripheral branches of the hepatic vein; Vv~2~, invasion of (or tumor thrombus in) the right, middle, or left hepatic vein, the inferior right hepatic vein, or the short hepatic vein; Vv~3~, invasion of (or tumor thrombus in) the inferior vena cava.

Among patients with ICC, tumor diameter was ≤2 cm in 12.6%, 2--5 cm in 53.4%, and 5--10 cm in 28.1% of patients, and 84.9% had unifocal disease.

### Local ablation therapy {#hepr13438-sec-0012}

Local ablation therapy was performed in 6174 patients with HCC. Percutaneous ethanol injection therapy was performed in 7.4%, percutaneous microwave coagulation therapy in 3.2%, and radiofrequency ablation in 81.5% (Table [11](#hepr13438-tbl-0011){ref-type="table"}). The treatment route was percutaneous for 88.8%. The percentage with unifocal disease was 89.2%. Tumor diameter was ≤2 cm in 64.6% and 2--3 cm in 26.2% of patients. The response assessed at 3 months after treatment initiation was complete response (CR) in 86.0%, partial response (PR) in 5.7%, stable disease (SD) in 3.6%, and progressive disease (PD) in 4.7% of patients. The corresponding response assessed at 6 months after treatment initiation was 83.0%, 5.0%, 2.7%, and 8.7%.

###### 

Local ablation therapy

  ----------------------------------
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For all parameters, *n* is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of *n*.

CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; TE2, treatment effect in target lesion (partial response); TE1, treatment effect in target lesion (progressive disease)TE3, treatment effect in target lesion (partial response); TE4a; treatment effect in target lesion (complete response with ablative margin); TE4b, treatment effect in target lesion (complete response without ablative margin).

### TACE {#hepr13438-sec-0013}

TACE was carried out in 8334 patients with HCC. Lipiodol alone was used in 16.0%, gelatin sponge alone in 2.2%, and lipiodol plus gelatin sponge particles in 78.7% of patients (Table [12](#hepr13438-tbl-0012){ref-type="table"}). In addition, 93.6% of patients were also being treated together with anticancer cytotoxic agents. The scope of embolization was less than one segment for 36.6%, at least one segment but less than one lobe for 40.3%, one lobe or more for 16.6%, and the entire liver for 6.5%. The response assessed at 3 months after treatment initiation was CR in 41.0%, PR in 21.8%, SD in 15.7%, and PD in 21.6% of patients. The corresponding response assessed at 6 months after treatment initiation was 40.1%, 17.3%, 12.1%, and 30.5%.

###### 

Transcatheter arterial chemoembolization

+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
|                                                             | Hepatocellular carcinoma | Intrahepatic cholangiocarcinoma | Combined hepatocellular cholangiocarcinoma |
|                                                             |                          |                                 |                                            |
|                                                             | *n* (%)                  | *n* (%)                         | *n* (%)                                    |
+:============================================================+==========================+=================================+============================================+
| Transarterial therapy                                       | *n* = 16 920             | *n* = 76                        | *n* = 115                                  |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Not performed                                               | 8586 (50.7)              | 697 (91.6)                      | 74 (64.3)                                  |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Performed                                                   | 8334 (49.3)              | 64 (8.4)                        | 41 (35.7)                                  |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Transcatheter arterial chemoembolization                    | *n* = 8283               | *n* = 63                        | *n* = 41                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Not performed                                               | 729 (8.8)                | 24 (38.1)                       | 11 (26.8)                                  |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Performed                                                   | 7554 (91.2)              | 39 (61.9)                       | 30 (73.2)                                  |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Therapy through implanted catheter system                   | *n* = 7102               | *n* = 56                        | *n* = 41                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Not performed                                               | 6488 (91.4)              | 42 (75.0)                       | 32 (78.0)                                  |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Performed                                                   | 614 (8.6)                | 14 (25.0)                       | 9 (22.0)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Embolic agent                                               | *n* = 7012               | *n* = 33                        | *n* = 30                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Lipiodol alone                                              | 1125 (16.0)              | 8 (24.2)                        | 10 (33.3)                                  |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Gelatin sponge alone                                        | 157 (2.2)                | 1 (3.0)                         | 2 (6.7)                                    |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Lipiodol + gelatin sponge                                   | 5518 (78.7)              | 22 (66.7)                       | 17 (56.7)                                  |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Other                                                       | 212 (3.0)                | 2 (6.1)                         | 1 (3.3)                                    |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Lipiodol dose                                               | *n* = 5250               | *n* = 18                        | *n* = 20                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Not used                                                    | 2 (0.0)                  | 0 (0.0)                         | 0 (0.0)                                    |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 0.1--1.0                                                    | 440 (8.4)                | 0 (0.0)                         | 1 (5.0)                                    |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 1.1--3.0                                                    | 2002 (38.1)              | 5 (27.8)                        | 4 (20.0)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 3.1--5.0                                                    | 1439 (27.4)              | 7 (38.9)                        | 10 (50.0)                                  |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 5.1--7.0                                                    | 559 (10.6)               | 3 (16.7)                        | 2 (10.0)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 7.1--10.0                                                   | 662 (12.6)               | 3 (16.7)                        | 3 (15.0)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>10                                                        | 146 (2.8)                | 0 (0.0)                         | 0 (0.0)                                    |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Combination with chemotherapy agents                        | *n* = 7804               | *n* = 38                        | *n* = 30                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Doxorubicin                                                 | 399                      | 2                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Epirubicin                                                  | 4281                     | 16                              | 19                                         |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Mitomycin                                                   | 1008                     | 4                               | 3                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Cisplatin                                                   | 1416                     | 10                              | 6                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| SMANCS                                                      | 203                      | 3                               | 1                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Miriplatin                                                  | 131                      | 0                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 5FU                                                         | 97                       | 1                               | 1                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Interferon                                                  | 17                       | 1                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Other                                                       | 252                      | 1                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Percentages not calculated as multiple choices were allowed |                          |                                 |                                            |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Area of embolization                                        | *n* = 6385               | *n* = 33                        | *n* = 24                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \<1 segment                                                 | 2339 (36.6)              | 10 (30.3)                       | 3 (12.5)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥1 segment to \<1 lobe                                      | 2574 (40.3)              | 12 (36.4)                       | 10 (41.7)                                  |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥1 lobe to \< entire liver                                  | 1058 (16.6)              | 9 (27.3)                        | 8 (33.3)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Entire liver                                                | 414 (6.5)                | 2 (6.1)                         | 3 (12.5)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Complications                                               | *n* = 241                | *n* = 2                         | *n* = 0                                    |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Acute cholecystitis                                         | 26                       | 1                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Biloma                                                      | 10                       | 0                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hepatic abscess                                             | 27                       | 0                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hepatic infarction                                          | 11                       | 0                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Liver failure                                               | 48                       | 0                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Tumor rupture                                               | 9                        | 0                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Gastrointestinal hemorrhage                                 | 10                       | 0                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Pulmonary infarction                                        | 0                        | 0                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Spinal cord injury                                          | 0                        | 0                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Other                                                       | 100                      | 1                               | 0                                          |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Percentages not calculated as multiple choices were allowed |                          |                                 |                                            |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Direct response assessment                                  | *n* = 5602               | *n* = 28                        | *n* = 22                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| TE4a                                                        | 1134 (20.2)              | 5 (17.9)                        | 1 (4.5)                                    |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| TE4b                                                        | 1494 (26.7)              | 3 (10.7)                        | 4 (18.2)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| TE3                                                         | 1459 (26.0)              | 9 (32.1)                        | 6 (27.3)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| TE2                                                         | 1053 (18.8)              | 6 (21.4                         | 7 (31.8)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| TE1                                                         | 325 (5.8)                | 3 (10.7)                        | 2 (9.1)                                    |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Overall response at 3 months                                | *n* = 5128               | *n* = 23                        | *n* = 19                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| CR                                                          | 2100 (41.0)              | 7 (30.4)                        | 3 (15.8)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| PR                                                          | 1118 (21.8)              | 5 (21.7)                        | 4 (21.1)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| SD                                                          | 803 (15.7)               | 5 (21.7)                        | 6 (31.6)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| PD                                                          | 1107 (21.6)              | 6 (26.1)                        | 6 (31.6)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Overall response at 6 months                                | *n* = 4505               | *n* = 21                        | *n* = 16                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| CR                                                          | 1806 (40.1)              | 5 (23.8)                        | 2 (12.5)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| PR                                                          | 781 (17.3)               | 5 (23.8)                        | 3 (18.8)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| SD                                                          | 545 (12.1)               | 2 (9.5)                         | 3 (18.8)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| PD                                                          | 1373 (30.5)              | 9 (42.9)                        | 8 (50.0)                                   |
+-------------------------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+

For all parameters, *n* is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of *n*.

5FU, fluorouracil; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; SMANCS, styrene maleic acid neocarzinostatin; TE1, treatment effect in target lesion (progressive disease); TE2, treatment effect in target lesion (partial response); TE3, treatment effect in target lesion (partial response); TE4a; treatment effect in target lesion (complete response with ablative margin); TE4b, treatment effect in target lesion (complete response without ablative margin).

### Systemic chemotherapy {#hepr13438-sec-0014}

Systemic chemotherapy was carried out in 372 patients with HCC. The response assessed at 3 months after treatment initiation was CR in 3.3%, PR in 13.5%, SD in 21.4%, and PD in 61.9%. Systemic chemotherapy was carried out for 196 patients with ICC. The route of administration was intravenous for 80.6% and oral for 17.9%. The response assessed at 3 months after treatment initiation was CR in 4.2%, PR in 15.0%, SD in 30.8%, and PD in 50.0% of patients (Table [13](#hepr13438-tbl-0013){ref-type="table"}).

###### 

Systemic chemotherapy

  ----------------------------------
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5FU, fluorouracil; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; SMANCS, styrene maleic acid neocarzinostatin; TE1, treatment effect in target lesion (progressive disease); TE2, treatment effect in target lesion (partial response); TE3, treatment effect in target lesion (partial response); TE4a; treatment effect in target lesion (complete response with ablative margin); TE4b, treatment effect in target lesion (complete response without ablative margin).

### Pathology {#hepr13438-sec-0015}

A pathological diagnosis was obtained for 44.7% of patients with HCC. Of these, 17.6% were made from a biopsy alone, 79.6% from a resected specimen alone, and 2.8% from a biopsy and resected specimen. In addition, 55.3% of patients had no pathological diagnosis, and the rate of diagnosis by biopsy had decreased since previous surveys, and the number of patients without a pathological diagnosis had increased. The histological grade of HCC was well differentiated in 24.9%, moderately differentiated in 62.8%, and poorly differentiated in 11.7% of patients (Table [14](#hepr13438-tbl-0014){ref-type="table"}). ICC was well differentiated in 18.5%, moderately differentiated in 58.0%, and poorly differentiated in 20.3% of patients (Table [15](#hepr13438-tbl-0015){ref-type="table"}). Table [16](#hepr13438-tbl-0016){ref-type="table"} shows details of pathological diagnosis. The non‐cancerous part of the liver in patients with HCC was normal in 4.6%, showed chronic hepatitis or fibrosis in 30.8%, and showed cirrhosis in 64.6%; in patients with ICC, it was normal in 66.7%, showed chronic hepatitis or fibrosis in 33.8%, and showed cirrhosis in 0.0%.

###### 

Histological grade of hepatocellular carcinoma

+------------+---------------------+---------------------------+-----------------------+------------------+-------------------------+-------------+
|            | Well differentiated | Moderately differentiated | Poorly differentiated | Undifferentiated | Fibrolamellar carcinoma | Sarcomatous |
|            |                     |                           |                       |                  |                         |             |
|            | *n* (%)             | *n* (%)                   | *n* (%)               | *n* (%)          | *n* (%)                 | *n* (%)     |
+:==========:+:====================+:==========================+:======================+:=================+:========================+:============+
| *n* = 7620 | 1900                | 4787                      | 890                   | 34               | 3                       | 6           |
+------------+---------------------+---------------------------+-----------------------+------------------+-------------------------+-------------+
| (24.9)     | (62.8)              | (11.7)                    | (0.4)                 | (0.0)            | (0.1)                   |             |
+------------+---------------------+---------------------------+-----------------------+------------------+-------------------------+-------------+

###### 

Histological grade of intrahepatic cholangiocarcinoma

+-----------+------------------------------------+------------------------------------------+--------------------------------------+--------------+
|           | Well differentiated adenocarcinoma | Moderately differentiated adenocarcinoma | Poorly differentiated adenocarcinoma | Special type |
|           |                                    |                                          |                                      |              |
|           | *n* (%)                            | *n* (%)                                  | *n* (%)                              | *n* (%)      |
+:==========+:===================================+:=========================================+:=====================================+:=============+
| *n* = 612 | 113                                | 355                                      | 124                                  | 20           |
+-----------+------------------------------------+------------------------------------------+--------------------------------------+--------------+
|           | (18.5)                             | (58.0)                                   | (20.3)                               | (3.3)        |
+-----------+------------------------------------+------------------------------------------+--------------------------------------+--------------+

###### 

Pathological findings from resected specimen or biopsy specimen

+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
|                                            | Hepatocellular carcinoma | Intrahepatic cholangiocarcinoma | Combined hepatocellular cholangiocarcinoma |
|                                            |                          |                                 |                                            |
|                                            | *n* (%)                  | *n* (%)                         | *n* (%)                                    |
+:===========================================+==========================+=================================+============================================+
| Capsule formation                          | *n* = 6398               | *n* = 553                       | *n* = 93                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| fc (−)                                     | 1640 (25.6)              | 512 (92.6)                      | 54 (58.1)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| fc (+)                                     | 4758 (74.4)              | 41 (7.4)                        | 39 (41.9)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Capsule invasion                           | *n* = 4641               | *n* = 40                        | *n* = 35                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| fc‐inf (−)                                 | 1323 (28.5)              | 15 (37.5)                       | 8 (22.9)                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| fc‐inf (+)                                 | 3318 (71.5)              | 25 (62.5)                       | 27 (77.1)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Septum formation                           | *n* = 6177               | *n* = 525                       | *n* = 80                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| sf (−)                                     | 2174 (35.2)              | 463 (88.2)                      | 29 (36.3)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| sf (+)                                     | 4003 (64.8)              | 62 (11.8)                       | 51 (63.8)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Serosal invasion                           | *n* = 6279               | *n* = 554                       | *n* = 79                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| s~0~                                       | 5509 (87.7)              | 373 (67.3)                      | 63 (79.7)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| s~1~                                       | 605 (9.6)                | 133 (24.0)                      | 13 (16.5)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| s~2~                                       | 84 (1.3)                 | 44 (7.9)                        | 2 (2.5)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| s~3~ (rupture)                             | 81 (1.3)                 | 4 (0.7)                         | 1 (1.3)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Lymph node metastasis                      | *n* = 5441               | *n* = 546                       | *n* = 84                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| n~0~                                       | 5384 (99.0)              | 384 (70.3)                      | 73 (86.9)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| n~1~                                       | 57 (1.0)                 | 162 (29.7)                      | 11 (13.1)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Portal vein invasion                       | *n* = 6560               | *n* = 578                       | *n* = 95                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vp~0~                                      | 4795 (73.1)              | 307 (53.1)                      | 54 (56.8)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vp~1~                                      | 1341 (20.4)              | 169 (29.2)                      | 28 (29.5)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vp~2~                                      | 190 (2.9)                | 41 (7.1)                        | 8 (8.4)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vp~3~                                      | 168 (2.6)                | 50 (8.7)                        | 5 (5.3)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vp~4~                                      | 66 (1.0)                 | 11 (1.9)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hepatic vein invasion                      | *n* = 6560               | *n* = 573                       | *n* = 94                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vv~0~                                      | 5812 (88.6)              | 406 (70.9)                      | 76 (80.9)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vv~1~                                      | 607 (9.3)                | 134 (23.4)                      | 14 (14.9)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vv~2~                                      | 88 (1.3)                 | 25 (4.4)                        | 4 (4.3)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vv~3~                                      | 53 (0.8)                 | 8 (1.4)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hepatic artery invasion                    | *n* = 6474               | *n* = 549                       | *n* = 81                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| va~0~                                      | 6413 (99.1)              | 505 (92.0)                      | 81 (100.0)                                 |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| va~1~                                      | 54 (0.8)                 | 27 (4.9)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| va~2~                                      | 4 (0.1)                  | 6 (1.1)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| va~3~                                      | 3 (0.0)                  | 11 (2.0)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Bile duct invasion                         | *n* = 6507               | *n* = 550                       | *n* = 93                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| b~0~                                       | 6284 (96.6)              | 272 (49.5)                      | 80 (86.0)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| b~1~                                       | 137 (2.1)                | 107 (19.5)                      | 8 (8.6)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| b~2~                                       | 39 (0.6)                 | 64 (11.6)                       | 2 (2.2)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| b~3~                                       | 33 (0.5)                 | 76 (13.8)                       | 2 (2.2)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| b~4~                                       | 14 (0.2)                 | 31 (5.6)                        | 1 (1.1)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Intrahepatic metastasis                    | *n* = 6265               | *n* = 555                       | *n* = 88                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| im~0~ (no metastasis)                      | 5394 (86.1)              | 465 (83.8)                      | 69 (78.4)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| im~s~ (within subsegment)                  | 170 (2.7)                | 14 (2.5)                        | 3 (3.4)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| im~1~ (within 1 segment)                   | 394 (6.3)                | 41 (7.4)                        | 8 (9.1)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| im~2~ (within 2 segment)                   | 205 (3.3)                | 23 (4.1)                        | 5 (5.7)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| im~3~ (within 3 segment)                   | 102 (1.6)                | 12 (2.2)                        | 3 3.4)                                     |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Invasion of surgical margins               | *n* = 6334               | *n* = 570                       | *n* = 91                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| sm (+) with tumor exposure                 | 467 (7.4)                | 93 (16.3)                       | 14 (15.4)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| sm (−) 0 mm                                | 566 (8.9)                | 38 (6.7)                        | 5 (5.5)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| sm (−) ≤5 mm                               | 1340 (21.2)              | 89 (15.6)                       | 17 (18.7)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| sm (−) ≤10 mm                              | 565 (8.9)                | 44 (7.7)                        | 5 (5.5)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| sm (−) \>10 mm                             | 485 (7.7)                | 44 (7.7)                        | 4 (4.4)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| sm (−) distance unknown                    | 2911 (46.0)              | 262 (46.0)                      | 46 (50.5)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Findings in non‐cancerous liver parenchyma | *n* = 6283               | *n* = 531                       | *n* = 92                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Normal                                     | 521 (8.3)                | 315 (59.3)                      | 13 (14.1)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Chronic hepatitis, liver fibrosis          | 3106 (49.4)              | 167 (31.5)                      | 49 (53.3)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Liver cirrhosis                            | 2656 (42.3)              | 49 (9.2)                        | 30 (32.6)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Fibrosis (new Inuyama classification)      | *n* = 5020               | *n* = 329                       | *n* = 70                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| F~0~ (normal)                              | 411 (8.2)                | 176 (53.5)                      | 8 (11.4)                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| F~1~                                       | 763 (15.2)               | 68 (20.7)                       | 11 (15.7)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| F~2~                                       | 939 (18.7)               | 32 (9.7)                        | 13 (18.6)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| F~3~                                       | 852 (17.0)               | 19 (5.8)                        | 15 (21.4)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| F~4~ (liver cirrhosis)                     | 2055 (40.9)              | 34 (10.3)                       | 23 (32.9)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Activity (new Inuyama classification)      | *n* = 3300               | *n* = 231                       | *n* = 46                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| A~0~                                       | 482 (14.6)               | 130 (56.3)                      | 11 (23.9)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| A~1~                                       | 1585 (48.0)              | 74 (32.0)                       | 20 (43.5)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| A~2~                                       | 1097 (33.2)              | 24 (10.4)                       | 14 (30.4)                                  |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| A~3~                                       | 136 (4.1)                | 3 (1.3)                         | 1 (2.2)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+

For all parameters, *n* is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of *n*.

A~0~, no necroinflammatory reaction; A~1~, mild necroinflammatory reaction; A~2~, moderate necroinflammatory reaction; A~3~, severe necroinflammatory reaction; proper hepatic artery; b~0~, no invasion of bile duct, b1, branches of the bile duct, but not of second order branches; b~2~, invasion of (or tumor thrombus in) the second order branches of the bile duct; b~3~, invasion of (or tumor thrombus in) the first order branches of the bile duct; b~4~, invasion of (or tumor thrombus in) the common hepatic duct; F~1~, fibrous expansion of portal tract; F~2~, fibrous septa formation, usually incomplete; F~3~, bridging fibrous formation accompanying lobular distortion; fc (−), absence of capsule formation; fc (+), presence of capsule formation; b0, absence of invasion of the bile ducts; b1, invasion of (or tumor thrombus in) the third order or more peripheral; fc‐inf (−), absence of cancerous infiltration of the tumor capsule; fc‐inf (+), presence of cancerous infiltration of the tumor capsule; im~1~, intrahepatic metastasis within the subsegment in which the principal tumor is located; im~2~, intrahepatic metastasis in two segments; im~3~, intrahepatic metastasis to three or more segments; im~s~, intrahepatic metastasis within the subsegment in which the principal tumor is located; sf (−), absence of formation of a fibrous septum within the tumor; sf (+), presence of fibrous septum within the tumor; s~0~, absence of invasion of the serosa; s~1~, tumor invasion of the serosa; s~2~, tumor invasion of adjacent organs; s~3~, tumor rupture with intraperitoneal bleeding; va~0~, absence of invasion of the hepatic artery; va~1~, invasion distal to the second order branches of the hepatic artery, but not of the second order branches; va~2~, invasion to the second order branches of the hepatic artery; va~3~, invasion to the left or right hepatic artery, or the im~0~, absence of intrahepatic metastasis; vp~0~, absence of invasion of (or tumor thrombus in) the portal vein; vp~1~, invasion of (or tumor thrombus in) distal to the second order branches of the portal vein, but not of the second order branches; vp~2~, invasion of (or tumor thrombus in) second order branches of the portal vein; vp~3~, invasion of (or tumor thrombus in) first order branches of the portal vein; vp~4~, invasion of (or tumor thrombus in) the main trunk of the portal vein and/or contra‐lateral portal vein branch to the primarily involved lobe; vv~0~, absence of invasion of (or tumor thrombus in) the hepatic vein; vv~1~, invasion of (or tumor thrombus in) peripheral branches of the hepatic vein; vv~2~, invasion of (or tumor thrombus in) the right, middle, or left hepatic vein, the inferior right hepatic vein, or the short hepatic vein; vv~3~, invasion of (or tumor thrombus in) the inferior vena cava.

### Recurrence {#hepr13438-sec-0016}

Recurrence during the survey period (within 2 years of diagnosis) was reported in 34.3% of patients with HCC. The most frequently performed treatment for intrahepatic recurrence was TACE at 40.2%, followed by local ablation therapy at 24.9%. The most common sites of extrahepatic recurrence were the lungs, bone, and lymph nodes. The most frequently performed treatments for distant recurrence were systemic chemotherapy (total includes both cytotoxic chemotherapy agents and molecularly targeted agents), radiotherapy, and surgery, in that order.

### Autopsy {#hepr13438-sec-0017}

Autopsies were carried out for a total of 91 patients with primary liver cancer. HCC was found in 85 patients. The rate of cirrhosis among autopsied patients with HCC was 64.6%, and rates of invasion of the portal vein, hepatic veins, and bile duct were 54.5%, 40.4%, and 18.7%, respectively. Extrahepatic spread was most frequently detected in the lungs (31.5%), lymph nodes (19.0%), and bone (16.7%). For ICC, the most common sites of extrahepatic spread were the intraperitoneal organs and the lungs, and the rate of lymph node metastasis was 75.0% (Table [17](#hepr13438-tbl-0017){ref-type="table"}).

###### 

Pathological findings on autopsy

+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
|                                            | Hepatocellular carcinoma | Intrahepatic cholangiocarcinoma | Combined hepatocellular cholangiocarcinoma |
|                                            |                          |                                 |                                            |
|                                            | *n* (%)                  | *n* (%)                         | *n* (%)                                    |
+:===========================================+==========================+=================================+============================================+
| Autopsy                                    | *n* = 2855               | *n* = 248                       | *n* = 35                                   |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No                                         | 2770 (97.0)              | 242 (97.6)                      | 35 (100.0)                                 |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Yes                                        | 85 (3.0)                 | 6 (2.4)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Liver weight                               | *n* = 56                 | *n* = 5                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Not measured                               | 7 (12.5)                 | 2 (40.0)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| 400--499                                   | 0 (0.0)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤599                                       | 1 (1.8)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤699                                       | 2 (3.6)                  | 1 (20.0)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤799                                       | 4 (7.1)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤899                                       | 5 (8.9)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤999                                       | 6 (10.7)                 | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1099                                      | 2 (3.6)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1199                                      | 1 (1.8)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1299                                      | 1 (1.8)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1399                                      | 7 (12.5)                 | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1499                                      | 1 (1.8)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1599                                      | 4 (7.1)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1699                                      | 2 (3.6)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1799                                      | 1 (1.8)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1899                                      | 2 (3.6)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1999                                      | 3 (5.4)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≥2000                                      | 7 (12.5)                 | 2 (40)                          | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Maximum tumor diameter                     | n = 54                   | n = 3                           | n = 0                                      |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤1 cm                                      | 2 (3.7)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤2 cm                                      | 5 (9.3)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤3 cm                                      | 5 (9.3)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤5 cm                                      | 12 (22.2)                | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤10 cm                                     | 18 (33.3)                | 1 (33.3)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤15 cm                                     | 6 (11.1)                 | 2 (66.7)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤20 cm                                     | 5 (9.3)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| ≤25 cm                                     | 1 (1.9)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| \>25 cm                                    | 0 (0.0)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Capsule formation                          | *n* = 34                 | *n* = 2                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| fc (−)                                     | 11 (32.4)                | 2 (100.0)                       | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| fc (+)                                     | 23 (67.6)                | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Portal vein invasion                       | *n* = 5                  | *n* = 3                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vp~0~                                      | 25 (45.5)                | 3 (100.0)                       | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vp~1~                                      | 9 (16.4)                 | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vp~2~                                      | 4 (7.3)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vp~3~                                      | 6 (10.9)                 | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vp~4~                                      | 11 (20.0)                | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hepatic vein invasion                      | *n* = 52                 | *n* = 3                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vv~0~                                      | 31 (59.6)                | 3 (100.0)                       | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vv~1~                                      | 6 (11.5)                 | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vv~2~                                      | 5 (9.6)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| vv~3~                                      | 10 (19.2)                | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Hepatic artery invasion                    | *n* = 42                 | *n* = 3                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| va~0~                                      | 38 (90.5)                | 3 (100.0)                       | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| va~1~                                      | 3 (7.1)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| va~2~                                      | 1 (2.4)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| va~3~                                      | 0 (0.0)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Bile duct invasion                         | *n* = 48                 | *n* = 3                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| b~0~                                       | 39 (81.3)                | 3 (100.0)                       | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| b~1~                                       | 1 (2.1)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| b~2~                                       | 3 (6.3)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| b~3~                                       | 4 (8.3)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| b~4~                                       | 1 (2.1)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Intrahepatic metastasis                    | *n* = 54                 | *n* = 3                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| im~0~                                      | 22 (40.7)                | 1 (33.3)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| im~s~                                      | 0 (0.0)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| im~1~                                      | 5 (9.3)                  | 1 (33.3)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| im~2~                                      | 8 (14.8)                 | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| im~3~                                      | 19 (35.2)                | 1 (33.3)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Serosal invasion                           | *n* = 47                 | *n* = 3                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| s~0~                                       | 31 (66.0)                | 3 (100.0)                       | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| s~1~                                       | 6 (12.8)                 | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| s~2~                                       | 4 (8.5)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| s~3~ (rupture)                             | 6 (12.8)                 | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Peritoneal dissemination                   | *n* = 61                 | *n* = 4                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No                                         | 51 (83.6)                | 2 (50.0)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Yes                                        | 10 (16.4)                | 2 (50.0)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Ascites                                    | *n* = 72                 | *n* = 4                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No                                         | 13 (18.1)                | 1 (25.0)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Yes                                        | 59 (81.9)                | 3 (75.0)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Findings in non‐cancerous liver parenchyma | *n* = 65                 | *n* = 3                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Normal                                     | 3 (4.6)                  | 2 (66.7)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Chronic hepatitis, liver fibrosis          | 20 (30.8)                | 1 (33.3)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Liver cirrhosis                            | 42 (64.6)                | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Extrahepatic metastasis                    | *n* = 53                 | *n* = 6                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Lung                                       | 23 (43.4)                | 3 (50.0)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Bone                                       | 11 (20.8)                | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Brain                                      | 0 (0.0)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Intraperitoneal organs                     | 7 (13.2)                 | 3 (50.0)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Adrenal gland                              | 6 (11.3)                 | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Skin                                       | 0 (0.0)                  | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Other                                      | 6 (11.3)                 | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Lymph node metastasis                      | *n* = 63                 | *n* = 4                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| n~0~                                       | 51 (81.0)                | 1 (25.0)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| n~1~                                       | 12 (19.0)                | 3 (75.0)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Esophagus/gastric varices                  | *n* = 63                 | *n* = 4                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No                                         | 29 (46.0)                | 4 (100.0)                       | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Yes                                        | 34 (54.0)                | 0 (0.0)                         | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Splenomegaly                               | *n* = 63                 | *n* = 4                         | *n* = 0                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| No                                         | 31 (49.2)                | 3 (75.0)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+
| Yes                                        | 32 (50.8)                | 1 (25.0)                        | 0 (0.0)                                    |
+--------------------------------------------+--------------------------+---------------------------------+--------------------------------------------+

For all parameters, *n* is the total number of patients, excluding those in the "unknown" category, and (%) is the percentage of *n*.

b~0~, no invasion of bile duct, b~1~, branches of the bile duct, but not of second order branches; b~2~, invasion of (or tumor thrombus in) the second order branches of the bile duct; b~3~, invasion of (or tumor thrombus in) the first order branches of the bile duct; b~4~, invasion of (or tumor thrombus in) the common hepatic duct; fc (−), absence of capsule formation; fc (+), presence of capsule formation; fc‐inf (−), absence of cancerous infiltration of the tumor capsule; fc‐inf (+), presence of cancerous infiltration of the tumor capsule; im~0~, absence of intrahepatic metastasis; im~1~, intrahepatic metastasis within the subsegment in which the principal tumor is located; im~2~, intrahepatic metastasis in two segments; im~3~, intrahepatic metastasis to three or more segments; im~s~, intrahepatic metastasis within the subsegment in which the principal tumor is located; sf (−), absence of formation of a fibrous septum within the tumor; sf (+), presence of fibrous septum within the tumor; s~0~, absence of invasion of the serosa; s~1~, tumor invasion of the serosa; s~2~, tumor invasion of adjacent organs; s~3~,tumor rupture with intraperitoneal bleeding; va~0~, absence of invasion of the hepatic artery; va~1~, invasion distal to the second order branches of the hepatic artery, but not of the second order branches; va~2~, invasion to the second order branches of the hepatic artery; va~3~, invasion to the left or right hepatic artery, or the proper hepatic artery; vp~0~, absence of invasion of (or tumor thrombus in) the portal vein; ~vp1~, invasion of (or tumor thrombus in) distal to the second order branches of the portal vein, but not of the second order branches; vp~2~, invasion of (or tumor thrombus in) second order branches of the portal vein; vp~3~, invasion of (or tumor thrombus in) first order branches of the portal vein; vp~4~, invasion of (or tumor thrombus in) the main trunk of the portal vein and/or contra‐lateral portal vein branch to the primarily involved lobe; vv~0~, absence of invasion of (or tumor thrombus in) the hepatic vein; vv~1~, invasion of (or tumor thrombus in) peripheral branches of the hepatic vein; vv~2~, invasion of (or tumor thrombus in) the right, middle, or left hepatic vein, the inferior right hepatic vein, or the short hepatic vein; vv~3~, invasion of (or tumor thrombus in) the inferior vena cava.

Cumulative survival rates {#hepr13438-sec-0018}
=========================

Cumulative survival rates from the 15th to 20th surveys (1998--2009) {#hepr13438-sec-0019}
--------------------------------------------------------------------

Cumulative survival rates were calculated for patients with HCC, ICC, and combined HCC and ICC who were newly registered in the surveys from 1998 to 2009, and whose final outcome was survival or death (excluding unknown).

### Cumulative survival rates for hepatocellular carcinoma {#hepr13438-sec-0020}

Table [18](#hepr13438-tbl-0018){ref-type="table"} shows cumulative survival rates among the 100 394 patients with HCC registered during 1998 and 2009. Median survival time was 53.95 months, and 5‐ and 10‐year survival rates were 46.6% and 24.7% (Table [18](#hepr13438-tbl-0018){ref-type="table"}; Fig. [1](#hepr13438-fig-0001){ref-type="fig"}). Cumulative survival rates for resected HCC: median overall survival (OS) for all patients with a Child--Pugh grade A who underwent resection was 96.89 months, and 5‐ and 10‐year survival rates were 65.8% and 44.0% (Table [19](#hepr13438-tbl-0019){ref-type="table"}; Fig. [2](#hepr13438-fig-0002){ref-type="fig"}). The TNM stage was well correlated with survival (Table [19](#hepr13438-tbl-0019){ref-type="table"}; Fig. [3](#hepr13438-fig-0003){ref-type="fig"}). Maximum tumor diameter, number of tumors, and extent of portal invasion (Fig. [4](#hepr13438-fig-0004){ref-type="fig"}), as well as α‐fetoprotein (Fig. [5](#hepr13438-fig-0005){ref-type="fig"}), were also well correlated with survival (Table [19](#hepr13438-tbl-0019){ref-type="table"}).Cumulative survival rates for HCC treated with local ablation therapy: median OS for patients with a Child--Pugh grade A who underwent local ablation therapy was 81.41 months, and 5‐ and 10‐year survival rates were 63.8% and 23.2% (Fig. [6](#hepr13438-fig-0006){ref-type="fig"}). The number of tumors and tumor diameter were well correlated with cumulative survival rate (Table [20](#hepr13438-tbl-0020){ref-type="table"}).Cumulative survival rates for HCC treated with TACE: median OS for patients with a Child--Pugh grade A who underwent TACE was 46.06 months, and 5‐ and 10‐year survival rates were 40.0% and 11.3% (Table [21](#hepr13438-tbl-0021){ref-type="table"}; Fig. [7](#hepr13438-fig-0007){ref-type="fig"}). The number of tumors was well correlated with survival rate after TACE (Table [21](#hepr13438-tbl-0021){ref-type="table"}; Fig. [8](#hepr13438-fig-0008){ref-type="fig"}).

###### 

Cumulative overall survival rates in patients with hepatocellular carcinoma, who were registered between 1998 and 2009

                     Fig. No.                         Title       Category name     *n*     Median OS (months)   Survival rate (%)                                                          
  ----------------------------------------------- -------------- --------------- --------- -------------------- ------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------
   Fig. [1](#hepr13438-fig-0001){ref-type="fig"}   All patients                   100 394         53.95                82.8          71.5   61.9   53.6   46.6   40.7   35.7   31.3   27.9   24.7

![Overall survival among all 100 394 registered patients with hepatocellular carcinoma during 1998--2009. The median overall survival was 53.95 months, and 5‐ and 10‐year survival rates were 46.6% and 24.7%.](HEPR-50-15-g001){#hepr13438-fig-0001}

###### 

Cumulative survival rates for resected hepatocellular carcinoma (in patients registered between 1998 and 2009)

  Fig. No.                                        Title                    Category name   *n*      Median OS (months)   Survival rate (%)                                                           
  ----------------------------------------------- ------------------------ --------------- -------- -------------------- ------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------
                                                  All patients                             30 040   90.18                90.4                82.5   75.3   68.8   62.8   57.3   52.4   47.7   43.8   40.3
  Fig. [2](#hepr13438-fig-0002){ref-type="fig"}   Child--Pugh grade        Child--Pugh A   22 258   96.89                91.7                84.3   77.6   71.6   65.8   60.1   55.5   50.3   46.6   44.0
  Child--Pugh B                                   2136                     60.19           81.6     72.7                 62.4                55.0   50.0   42.7   36.4   33.7   23.2   --            
  Child--Pugh C                                   74                       39.26           67.4     53.3                 51.1                46.5   43.1   43.1   32.4   24.3   24.3   24.3          
  Fig. [3](#hepr13438-fig-0003){ref-type="fig"}   TNM stage by LCSGJ       Stage I         2810     124.42               97.2                94.6   90.0   84.9   79.3   74.9   69.3   64.3   59.5   51.0
  Stage II                                        13 859                   106.91          94.9     89.0                 82.5                76.3   70.5   64.2   59.1   53.6   49.6   47.4          
  Stage III                                       6681                     66.07           87.2     76.5                 67.3                59.1   53.1   47.5   42.6   38.2   34.8   30.9          
  Stage IVA                                       2186                     28.45           70.5     53.6                 43.8                37.8   32.2   28.3   25.7   23.0   20.3   18.9          
  Stage IVB                                       333                      15.34           57.1     40.5                 31.7                30.2   25.8   23.7   19.3   19.3   19.3   19.3          
                                                  Maximum tumor diameter   ≤2 cm           5478     118.05               96.1                92.4   87.0   80.8   74.3   69.2   64.0   58.3   54.5   47.5
  \>2 cm to ≤3 cm                                 7247                     99.48           94.9     88.9                 82.0                75.7   69.5   63.2   57.1   51.9   46.2   42.1          
  \>3 cm to ≤5 cm                                 8253                     87.23           92.1     84.2                 76.2                69.1   62.9   56.6   51.6   47.3   44.4   41.7          
  \>5 cm to ≤10 cm                                5858                     68.37           85.2     73.9                 65.3                58.6   53.2   48.2   45.1   40.4   37.7   36.1          
  \>10 cm                                         2352                     32.79           70.6     56.2                 48.5                42.7   39.2   35.8   32.8   29.8   27.1   26.4          
                                                  No. tumors               1               21 676   105.07               92.6                86.2   79.8   73.8   68.3   62.7   57.9   53.1   49.1   45.7
  2                                               4302                     71.72           88.9     79.1                 70.7                63.0   55.6   49.7   43.9   38.4   34.5   30.4          
  ≥3                                              3317                     40.54           78.7     64.7                 53.5                44.9   38.7   33.5   30.3   26.4   23.9   20.2          
  Fig. [4](#hepr13438-fig-0004){ref-type="fig"}   Portal vein invasion     Vp~0~           24 583   97.02                93.4                86.8   79.6   72.9   66.7   60.8   55.6   50.4   46.5   42.8
  Vp~1~                                           2479                     61.21           83.8     70.1                 62.3                55.1   50.7   45.9   41.1   38.9   33.9   28.9          
  Vp~2~                                           918                      25.86           67.3     51.5                 41.2                38.5   33.1   29.6   28.2   25.4   21.8   21.8          
  ≥Vp~3~                                          1101                     15.70           56.8     40.0                 33.1                28.6   24.9   22.4   22.0   21.5   19.9   19.9          
  Fig. [5](#hepr13438-fig-0005){ref-type="fig"}   AFP (ng/mL)              ≤20             14 319   114.43               95.2                89.6   83.5   77.3   71.5   65.9   60.9   55.8   51.9   48.1
  \>20 to ≤200                                    7044                     75.17           90.8     82.1                 73.6                65.9   59.1   52.0   46.5   40.3   36.1   30.9          
  \>200 to ≤400                                   1425                     72.71           87.8     76.8                 68.1                61.4   55.9   50.6   44.8   41.0   36.3   33.5          
  \>400 to ≤1000                                  1647                     65.02           85.7     75.5                 65.3                58.7   52.8   47.1   43.8   40.3   35.9   34.4          
  \>1000 to ≤10, 000                              2663                     62.23           81.0     71.5                 62.6                55.8   50.5   47.2   44.4   41.2   38.8   36.9          
  \>10 000                                        1619                     27.04           67.8     52.2                 45.2                42.2   39.1   36.3   33.9   32.6   29.2   29.2          

AFP, α‐fetoprotein; LCSGJ, Liver Cancer Study Group of Japan; TNM, tumor--node--metastasis; Vp~0~, absence of invasion of (or tumor thrombus in) the portal vein; Vp~1~, invasion of (or tumor thrombus in) distal to the second order branches of the portal vein, but not of the second order branches; Vp~2~, invasion of (or tumor thrombus in) second order branches of the portal vein; Vp~3~, invasion of (or tumor thrombus in) first order branches of the portal vein; vp~4~, invasion of (or tumor thrombus in) the main trunk of the portal vein and/or contra‐lateral portal vein branch to the primarily involved lobe.

![Overall survival by Child--Pugh grade in patients with hepatocellular carcinoma treated with resection (*n* = 30 040). The median overall survival for patients with a Child--Pugh grade A who underwent resection was 96.89 months, and 5‐ and 10‐year survival rates were 65.8% and 44.0%.](HEPR-50-15-g002){#hepr13438-fig-0002}

![Overall survival in patients with hepatocellular carcinoma treated with resection according to the TNM stage by the Liver Cancer Study Group of Japan.](HEPR-50-15-g003){#hepr13438-fig-0003}

![Overall survival according to portal vein invasion in patients with hepatocellular carcinoma treated with resection.](HEPR-50-15-g004){#hepr13438-fig-0004}

![Overall survival by serum α‐fetoprotein level in patients with hepatocellular carcinoma treated with resection.](HEPR-50-15-g005){#hepr13438-fig-0005}

![Overall survival by Child--Pugh grade in patients with hepatocellular carcinoma treated with local ablation therapy. The median overall survival for patients with a Child--Pugh grade A who underwent local ablation therapy was 81.41 months, and 5‐ and 10‐year survival rates were 63.8% and 23.2%.](HEPR-50-15-g006){#hepr13438-fig-0006}

###### 

Cumulative survival rates for hepatocellular carcinoma treated with local ablation therapy (in patients registered between 1998 and 2009)

  Fig. No.                                        Title                    Category name   *n*      Median OS (months)   Survival rate (%)                                                           
  ----------------------------------------------- ------------------------ --------------- -------- -------------------- ------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------
                                                  All patients                             27 181   67.19                94.3                85.2   75.0   64.6   55.0   47.1   39.8   33.8   28.9   24.3
  Fig. [6](#hepr13438-fig-0006){ref-type="fig"}   Child--Pugh grade        Child--Pugh A   15 517   81.41                97.0                90.2   82.3   73.5   63.8   55.8   47.8   40.0   33.5   23.2
  Child--Pugh B                                   5142                     52.63           90.7     77.6                 64.7                53.2   43.6   34.7   27.3   23.5   19.0   18.3          
  Child--Pugh C                                   541                      26.94           76.3     53.4                 40.9                30.0   20.8   16.0   14.8   13.3   13.3   13.3          
                                                  No. tumors               1               17 986   74.68                95.3                87.2   78.2   68.6   59.6   51.7   44.0   38.8   33.4   28.2
  2                                               5309                     60.12           93.4     83.5                 72.5                61.0   50.1   42.2   35.5   28.3   22.8   19.9          
  3                                               1986                     51.48           92.8     80.8                 66.8                53.0   43.3   35.0   28.4   21.6   18.7   15.1          
  4                                               688                      50.40           90.8     78.3                 64.7                52.0   44.1   32.9   28.4   21.0   18.5   12.7          
  ≥5                                              818                      40.80           87.4     69.8                 54.9                44.8   33.1   27.0   23.1   17.8   17.0   15.0          
                                                  Maximum tumor diameter   ≤1 cm           2034     86.67                96.8                90.8   82.6   75.2   65.9   57.5   51.6   44.5   38.2   29.9
  \>1 cm to ≤2 cm                                 13 151                   74.09           95.8     88.2                 79.1                69.1   60.1   51.5   43.3   36.9   31.4   26.1          
  \>2 cm to ≤3 cm                                 7387                     63.18           94.2     84.2                 72.7                61.6   51.6   43.7   36.4   31.0   26.7   22.8          
  \>3 cm to ≤5 cm                                 2732                     48.89           89.8     75.3                 63.1                50.5   40.9   35.1   30.2   25.6   20.2   18.2          
  \>5 cm                                          572                      46.39           83.4     68.5                 57.8                48.9   38.5   30.3   27.9   21.6   20.7   14.3          

OS, overall survival.

###### 

Cumulative survival rates for hepatocellular carcinoma treated with transcatheter arterial chemoembolization (in patients registered between 1998 and 2009)

  Fig. No.                                        Title               Category name   *n*              Survival rate (%)                                                           
  ----------------------------------------------- ------------------- --------------- -------- ------- ------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------
                                                  All patients                        22 695   37.62   82.3                65.2   51.7   40.1   32.0   25.3   20.5   16.9   15.1   11.8
  Fig. [7](#hepr13438-fig-0007){ref-type="fig"}   Child--Pugh grade   Child--Pugh A   12 134   46.06   87.2                72.6   59.9   48.5   40.0   32.2   26.0   21.3   19.0   11.3
  Child--Pugh B                                   4803                27.83           77.0     55.8    39.2                26.2   19.2   14.5   10.4   8.9    7.5    --            
  Child--Pugh C                                   686                 16.16           59.6     35.5    23.8                16.6   12.2   9.2    7.0    7.0    7.0    --            
  Fig. [8](#hepr13438-fig-0008){ref-type="fig"}   No. tumors          1               9406     47.34   87.1                73.6   61.4   49.4   41.1   33.4   27.6   23.5   20.6   15.3
  2                                               4347                41.07           86.3     69.5    55.5                41.7   31.3   24.0   18.6   13.5   12.4   10.4          
  3                                               2541                33.48           84.6     64.5    47.4                34.4   26.1   20.3   14.9   13.4   12.4   11.0          
  4                                               1232                31.47           84.5     61.5    42.9                32.3   24.2   17.6   14.0   9.3    9.3    8.0           
  ≥5                                              4565                21.19           68.1     46.1    32.8                23.8   18.2   14.7   12.6   10.3   8.6    6.6           

OS, overall survival.

![Overall survival by Child--Pugh grade in patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Cumulative survival rate by Child--Pugh score among patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization. The median overall survival for patients with a Child--Pugh grade A who underwent transcatheter arterial chemoembolization was 46.06 months, and 5‐ and 10‐year survival rates were 40.0% and 11.3%.](HEPR-50-15-g007){#hepr13438-fig-0007}

![Overall survival by number of tumors in patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization.](HEPR-50-15-g008){#hepr13438-fig-0008}

### Cumulative survival rates for intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma {#hepr13438-sec-0021}

Tables [22](#hepr13438-tbl-0022){ref-type="table"} and [23](#hepr13438-tbl-0023){ref-type="table"} show cumulative survival rates for patients with ICC (all patients and by patient factors) and combined HCC and ICC (all patients).

###### 

Cumulative survival rates for intrahepatic cholangiocarcinoma (in patients registered between 1998 and 2009)

  Fig. No.           Title                                 Category name       *n*      Median OS (months)   Survival rate (%)                                                           
  ------------------ ------------------------------------- ------------------- -------- -------------------- ------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------
                     All patients                                              4436     18.14                59.6                43.4   37.4   32.9   28.9   26.2   24.2   21.8   20.2   18.2
                     Hepatectomy                           Yes                 2412     43.27                78.5                61.0   53.8   47.5   41.9   38.8   35.9   32.9   30.7   28.6
  No                 263                                   33.31               71.5     53.4                 44.6                39.6   37.1   31.1   31.1   25.4   25.4   12.7          
                     Hepatectomy: maximum tumor diameter   ≤2 cm               244      --                   91.4                80.5   73.0   68.3   63.4   61.5   61.5   50.9   50.9   50.9
  \>2 cm to ≤5 cm    1144                                  53.72               84.3     68.2                 60.3                53.0   45.9   42.0   38.2   35.0   33.2   33.2          
  \>5 cm to ≤10 cm   739                                   22.67               68.1     47.4                 40.4                34.9   30.7   27.7   25.9   25.9   23.9   20.5          
  \>10 cm            149                                   17.41               62.8     42.4                 40.9                37.3   32.3   29.8   29.8   25.6   17.0   17.0          
                     Hepatectomy: No. tumors               1                   1, 925   54.28                81.8                66.0   59.3   52.9   46.8   43.4   40.9   36.9   35.1   32.2
  2                  143                                   27.50               78.8     57.0                 45.5                36.2   33.6   33.6   33.6   33.6   33.6   33.6          
  ≥3                 241                                   14.00               56.1     26.9                 19.4                13.7   11.1   9.7    7.3    7.3    3.6    --            
                     Hepatectomy: curability               Curability A or B   372      64.13                84.2                69.4   61.2   57.6   51.7   47.4   43.1   39.0   35.8   33.9
  Curability C       892                                   25.36               71.8     51.1                 44.1                37.1   31.5   29.0   27.1   22.9   22.9   22.9          
                     Hepatectomy: lymph node metastasis    N~0~                1612     64.26                85.6                70.2   62.7   56.0   51.0   48.3   45.4   41.4   40.4   40.4
  N~1~               645                                   16.07               61.2     36.1                 30.6                25.0   19.4   16.3   13.2   11.3   8.5    --            

OS, overall survival.

###### 

Cumulative survival rates for combined hepatocellular cholangiocarcinoma (in patients registered between 1998 and 2009)

  Fig. No.   Title          Category name   *n*    Median OS (months)   Survival rate (%)                                                           
  ---------- -------------- --------------- ------ -------------------- ------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------
             All patients                   708    19.78                60.8                44.8   37.9   34.0   30.2   28.4   24.9   22.4   20.7   17.7
             Hepatectomy    Yes             441    36.63                75.4                58.7   51.0   45.6   41.2   38.4   32.8   28.7   25.8   20.7
  No         108            17.91           60.5   34.2                 28.3                25.1   16.8   16.8   16.8   16.8   16.8   16.8          

OS, overall survival.

Changes in cumulative survival rate over time {#hepr13438-sec-0022}
---------------------------------------------

### Changes in survival over time for hepatocellular carcinoma {#hepr13438-sec-0023}

Cumulative survival rates were calculated by registration date for newly registered patients with HCC whose final outcome was survival or death (excluding unknown). Patients were grouped by 8‐year periods into four time period groups. Period 1 consisted of those registered in the fifth to eighth surveys (1978--1985), period 2 of those registered in the ninth to 12th surveys (1986--1993), period 3 of those registered in the 13th to 16th surveys, and period 4 of those registered in the 17th to 20th surveys (2002--2009; Table [24](#hepr13438-tbl-0024){ref-type="table"}; Fig. [9](#hepr13438-fig-0009){ref-type="fig"}). Cumulative survival rates (5‐year/10‐year) and median OS were 11.9%/5.0% and 4.99 months for period 1 (1978--1985, *n* = 5551), 31.9%/10.1% and 25.63 months for period 2 (1986--1993), 39.7%/20.6% and 42.97 months for period 3 (1994--2001, *n* = 53 775), and 50.4%/24.0% and 60.81 months for period 4 (2002--2009, *n* = 65 711). The number of new registrations has been increasing over time, and the prognosis of HCC is improving dramatically (Table [24](#hepr13438-tbl-0024){ref-type="table"}; Fig. [9](#hepr13438-fig-0009){ref-type="fig"}).

###### 

Cumulative survival rates from the 5th to 20th surveys (patients registered between 1978 and 2009)

  Fig. No.                                         Title                                                          Category name              *n*    Median OS (months)   Survival rate (%)                                                          
  ------------------------------------------------ -------------------------------------------------------------- -------------------------- ------ -------------------- ------------------- ------ ------ ------ ------ ------ ------ ------ ----- -----
  Fig. [9](#hepr13438-fig-0009){ref-type="fig"}    All patients with hepatocellular carcinoma                     Registered in 1978--1985   5551   4.99                 33.9                23.4   18.1   14.9   11.9   9.6    8.3    7.1    5.9   5.0
  Registered in 1986--1993                         32 721                                                         25.63                      66.9   51.7                 40.5                31.9   25.5   20.5   16.9   14.1   11.7   10.1         
  Registered in 1994--2001                         53 775                                                         42.97                      78.4   65.6                 55.3                46.7   39.7   34.2   29.8   26.1   23.0   20.6         
  Registered in 2002--2009                         65 711                                                         60.81                      84.4   73.8                 64.8                57.0   50.4   44.3   39.1   32.7   28.4   24.0         
  Fig. [10](#hepr13438-fig-0010){ref-type="fig"}   All patients with intrahepatic cholangiocarcinoma              Registered in 1978--1985   338    3.71                 21.2                14.9   11.5   11.5   11.0   9.1    9.1    9.1    8.2   8.2
  Registered in 1986--1993                         1056                                                           7.56                       38.2   25.5                 20.6                16.8   14.1   11.7   10.3   9.6    8.0    7.7          
  Registered in 1994--2001                         4552                                                           17.02                      57.7   41.4                 33.0                27.1   22.6   19.6   17.4   15.2   13.4   12.2         
  Registered in 2002--2009                         3184                                                           20.60                      62.4   46.6                 40.4                35.8   30.9   28.0   23.7   21.4   21.4   10.7         
                                                   All patients with combined hepatocellular cholangiocarcinoma   Registered in 1978--1985   69     2.86                 15.5                7.7    7.7    6.2    6.2    3.1    3.1    3.1    3.1   3.1
  Registered in 1986--1993                         126                                                            19.55                      61.9   35.8                 29.0                23.7   22.6   21.4   18.7   17.3   17.3   17.3         
  Registered in 1994--2001                         330                                                            16.82                      55.5   39.6                 29.8                25.1   23.2   21.7   18.8   16.9   15.5   12.9         
  Registered in 2002--2009                         501                                                            24.02                      65.5   50.1                 43.0                39.2   33.6   31.0   28.8   --     --     --           

OS, overall survival.

![Improvement of overall survival among all patients with hepatocellular carcinoma according to the registration period. A comparison of cumulative overall survival among patients newly registered between 1978 and 2009 (*n* = 157 758) divided into four groups by registration date. The median overall survival and cumulative survival rates (5‐year/10‐year) were 4.99 months and 11.9%/5.0% for group 1 (1978--1985, *n* = 5551), 25.63 months and 31.9%/10.1% for group 2 (1986--1993), 42.97 months and 39.7%/20.6% for group 3 (1994--2001, *n* = 53 775), and 60.81 months and 50.4%/24.0% for group 4 (2002--2009, *n* = 65 711).](HEPR-50-15-g009){#hepr13438-fig-0009}

### Changes in survival over time for intrahepatic cholangiocarcinoma {#hepr13438-sec-0024}

Cumulative survival rate and median OS were calculated to determine how survival for ICC has changed over time. Median OS and survival rates (5‐year/10‐year) were 3.71 and 11.0%/8.2% for period 1 (*n* = 338), 7.56 months and 14.1%/7.7% for period 2 (*n* = 1056), 17.02 months and 22.6%/12.2% for period 3 (*n* = 4552), and 20.6 months and 30.9%/10.7% for period 4 (*n* = 3184). Survival has gradually improved over the years, although not as dramatically as for HCC (Table [24](#hepr13438-tbl-0024){ref-type="table"}; Fig. [10](#hepr13438-fig-0010){ref-type="fig"}).

![Improvement of overall survival among all patients with intrahepatic cholangiocarcinoma according to the registration period. A comparison of cumulative survival rates among patients newly registered between 1978 and 2009 (*n* = 9130). The median overall survival and survival rates (5‐year/10‐year) were 3.71 and 11.0%/8.2% for group 1 (*n* = 338), 7.56 months and 14.1%/7.7% for group 2 (*n* = 1056), 17.02 months and 22.6%/12.2% for group 3 (*n* = 4552), and 20.6 months and 30.9%/10.7% for group 4 (*n* = 3184).](HEPR-50-15-g010){#hepr13438-fig-0010}

#### Conclusion {#hepr13438-sec-0025}

Primary liver cancer is the fifth most common cause of cancer death in Japan after lung cancer, colorectal cancer, gastric cancer, and pancreatic cancer.[77](#hepr13438-bib-0077){ref-type="ref"} The number of deaths from HCC peaked at 34 510 in 2004, and has continued to decrease gradually every year since. Nevertheless, it is reported that \>28 000 people still die from HCC each year. Approximately 37.5% of the patients with primary liver cancer registered in the 20th Nationwide Follow‐up Survey of Primary Liver Cancer in Japan were newly registered.

Compared with the 19th survey, the population of patients with HCC in this survey was older at the time of clinical diagnosis, included more female patients, had smaller tumor diameters, and more frequently received radiofrequency ablation as local ablation therapy. Calculation of the median OS and cumulative survival rates for patients newly registered in the four time periods between 1978 and 2009 revealed marked improvement in survival rates for HCC, which can be attributed to advances in early diagnosis and treatment. The OS of HCC in Japan is number 1 in the world according to the comparison with the published data from other countries worldwide.[62](#hepr13438-bib-0062){ref-type="ref"}, [78](#hepr13438-bib-0078){ref-type="ref"} We believe that the large set of data from registered patients analyzed in this follow‐up survey will advance the research and treatment outcome of primary liver cancer.
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